



# Lipolysis of bone marrow adipocytes is required to fuel bone and the marrow niche during energy deficits

Ziru Li<sup>1</sup>, Emily Bowers<sup>2</sup>, Junxiong Zhu<sup>3,4</sup>, Hui Yu<sup>1</sup>, Julie Hardij<sup>1</sup>, Devika P Bagchi<sup>1</sup>, Hiroyuki Mori<sup>1</sup>, Kenneth T Lewis<sup>1</sup>, Katrina Granger<sup>1</sup>, Rebecca L Schill<sup>1</sup>, Steven M Romanelli<sup>1</sup>, Simin Abrishami<sup>2</sup>, Kurt D Hankenson<sup>3</sup>, Kanakadurga Singer<sup>1,2</sup>, Clifford J Rosen<sup>5</sup>, Ormond A MacDougald<sup>1,6\*</sup>

<sup>1</sup>University of Michigan Medical School, Department of Molecular & Integrative Physiology, Ann Arbor, United States; <sup>2</sup>University of Michigan Medical School, Department of Pediatrics, Ann Arbor, United States; <sup>3</sup>Department of Orthopedic Surgery, University of Michigan Medical School, Ann Arbor, United States; <sup>4</sup>Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; <sup>5</sup>Maine Medical Center Research Institute, Scarborough, United States; <sup>6</sup>University of Michigan Medical School, Department of Internal Medicine, Ann Arbor, United States

**Summary** To investigate roles for bone marrow adipocyte (BMA) lipolysis in bone homeostasis, we created a BMA-specific Cre mouse model in which we knocked out adipose triglyceride lipase (ATGL, *Pnpla2* gene). BMA-*Pnpla2*<sup>-/-</sup> mice have impaired BMA lipolysis, and increased size and number of BMAs at baseline. Although energy from BMA lipid stores is largely dispensable when mice are fed ad libitum, BMA lipolysis is necessary to maintain myelopoiesis and bone mass under caloric restriction. BMA-specific *Pnpla2* deficiency compounds the effects of caloric restriction on loss of trabecular bone in male mice, likely due to impaired osteoblast expression of collagen genes and reduced osteoid synthesis. RNA sequencing analysis of bone marrow adipose tissue reveals that caloric restriction induces dramatic elevations in extracellular matrix organization and skeletal development genes, and energy from BMA is required for these adaptations. BMA-derived energy supply is also required for bone regeneration upon injury, and maintenance of bone mass with cold exposure.

\*For correspondence: macdouga@umich.edu

**Competing interest:** The authors declare that no competing interests exist.

**Funding:** See page 22

**Received:** 09 March 2022

**Preprinted:** 21 March 2022

**Accepted:** 21 June 2022

**Published:** 22 June 2022

**Reviewing Editor:** Mone Zaidi, Icahn School of Medicine at Mount Sinai, United States

© Copyright Li et al. This article is distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use and redistribution provided that the original author and source are credited.

## Editor's evaluation

Through the cell selective deletion in bone marrow adipocytes (BMAs) of an enzyme for lipolysis, the authors demonstrate elegantly a role for this pathway in the maintenance of hematopoiesis and bone mass during periods of caloric stress, injury and energy restriction. This study establishes for the first time a role for the bone marrow adipocyte in energy balance.

## Introduction

Adipocytes are found throughout the body, and can be classified generally into white, brown, beige/BRITE and bone marrow adipose tissues (BMAT); however, many other niche depots exist, and adipocyte subpopulations within specific depots have recently been identified (*Bagchi et al., 2018; Emont et al., 2022; Sárvári et al., 2021*). In an adult human, 50–70% of the bone marrow cavity is filled with BMAT, which contributes ~10% of the total body fat mass (*Cawthorn et al., 2014*). BMAT was

identified in the 19th century, and has been assumed to play significant roles in local bone homeostasis and hematopoiesis (Li et al., 2018; Li and MacDougald, 2021). Clinical associations generally demonstrate inverse relationships between BMAT and bone mass (Shen et al., 2007), or BMAT and circulating immune cells (Polineni et al., 2020), which may be due to the interactions between cells within the bone marrow niche. In addition to bone marrow adipocytes (BMAd), the bone marrow niche contains osteoblasts, osteoclasts, hematopoietic cells, stromal/mesenchymal cells, blood vessels, and nerves (Vogler and Murphy, 1988). The relationships between BMAd, bone cells, and hematopoietic cells are influenced by their shared location within bone, an anatomically restricted system, such that expansion of one cell type is by necessity at the expense of others. For example, elevated BMAT is inversely correlated with low bone mass of aging and diabetes, whereas expansion of BMAT is associated with multiple hematopoietic disorders (Li and MacDougald, 2021). Mechanistic links underlying these associations have proven challenging to investigate because these often involve complex intercellular, endocrine, and/or central mechanisms.

In addition to serving as an energy source, BMAd potentially influence the marrow niche through cell-to-cell contact, release of extracellular vesicles, and secretion of adipokines (e.g. adiponectin and leptin) and cytokines (e.g. adipisin, RANK ligand, and stem cell factor; Aaron et al., 2021; Li et al., 2018). Removal of these stimuli in mouse models of lipodystrophy, which lack BMAT, results in increased bone mass (Corsa et al., 2021; Zou et al., 2020; Zou et al., 2019). However, use of these models to investigate direct effects of BMAT depletion is confounded by concurrent loss of white and brown adipose depots, which also regulate bone mass through myriad mechanisms, including secretion of adipokines (Riddle and Clemens, 2017; Zou et al., 2019). Although loss of BMAT in lipodystrophic mice was integral to the original finding that BMAT is a negative regulator of hematopoiesis, positive effects of BMAT on hematopoiesis have also been observed; these differences are attributed to use of distinct animal models and analysis of different skeletal sites (Ambrosi et al., 2017; Naveiras et al., 2009; Zhou et al., 2017). In rodents, there are two readily identifiable BMAd populations: constitutive BMAT (cBMAT) and regulated BMAT (rBMAT) (Scheller et al., 2015). cBMAT typically exists in distal tibia and caudal vertebrae, appears early in life, and has the histological appearance of white adipose tissue. rBMAT is found in proximal tibia and distal femur, and is comprised of single or clustered BMAd interspersed with hematopoietic cells. Although cBMAT generally resists change in response to altered physiological states, rBMAT expands with aging, obesity, diabetes, caloric restriction (CR), irradiation, and estrogen deficiency, and is reduced by cold exposure,  $\beta$ 3-agonist, exercise, and vertical sleeve gastrectomy (Li et al., 2018; Li et al., 2019). These treatments also cause alterations to the skeleton and/or formation of blood cells, some of which may be secondary to effects on BMAd.

In contrast, BMAd have also been thought to fuel maintenance of bone and hematopoietic cellularity because of their shared physical location in the marrow niche. Indeed, Steele, 1884 wrote that fat in marrow 'nourishes the skeleton'; however, that conjecture has not been formally tested because current methods to target BMAd lack penetrance or cause recombination in other cell types, such as white adipocytes, osteoblasts, or bone marrow stromal cells, complicating the interpretation of interactions between BMAd and cells of the marrow niche. To circumvent this problem, we created a BMAd-specific Cre mouse model based on expression patterns of endogenous *Osterix* and *Adipoq*, and investigated the role of BMAd as a local energy source by deleting *ATGL/Pnpla2*, the rate-limiting enzyme of lipolysis. Consistent with *Pnpla2* deficiency in white and brown adipocytes (Ahmadian et al., 2011), BMAd-*Pnpla2*<sup>-/-</sup> mice have impaired BMAd lipolysis, resulting in hypertrophy and hyperplasia of BMAT. Despite significant increases in bone marrow adiposity, hematopoietic abnormalities of BMAd-*Pnpla2*<sup>-/-</sup> mice are negligible under basal conditions. However, the recovery of bone marrow myeloid lineages following sublethal irradiation is impaired with CR, and is further reduced by BMAd-*Pnpla2* deficiency. Similarly, the proliferative capacity of myeloid progenitors is also decreased with CR, and further inhibited in mice lacking BMAd-*Pnpla2*. Whereas alterations in bone parameters were not observed in ad libitum fed BMAd-*Pnpla2*<sup>-/-</sup> mice, bone loss occurred under conditions of elevated energy needs such as bone regeneration or cold exposure, or reduced energy availability such as CR. Reduction of bone mass in CR BMAd-*Pnpla2*<sup>-/-</sup> mice is likely due to impaired osteoblast functions such as expression of extracellular matrix genes and creation of osteoid. Gene profiling reveals that *Pnpla2* deletion largely blocks CR-induced genes within pathways of extracellular matrix organization and skeletal development,


indicating that BMAd-derived energy contributes to skeletal homeostasis under conditions of negative energy balance.

## Results

### Generation of a BMAd-specific Cre mouse model (BMAd-Cre)

Based on previous studies showing that *Osterix* traces to osteoblasts and BMAds, but not to white adipocytes (Chen and Long, 2013; Mizoguchi et al., 2014), we used CRISPR/Cas9 to create *Osterix-FLPo* mice with an in-frame fusion of *Osterix* and optimized *FLPo*, separated by a *P2A* self-cleaving sequence to allow independent functioning of the two proteins (Figure 1A). To validate tissue-specific expression and *FLPo* efficiency, we bred *Osterix-FLPo* mice to *FLPo*-dependent EGFP reporter mice, and observed EGFP-positive osteocytes, osteoblasts, BMAds, and a subset of marrow stromal cells within the bone (Figure 1B and C).

We next created *FLPo*-dependent *Adipoq-Cre* (FAC) mice, which contain an internal ribosome entry sequence (*IRES*) followed by *FLPo*-dependent *Cre* in reverse orientation within the 3'-untranslated region (UTR) of endogenous *Adipoq* gene (Figure 1D). *FLPo* expressed from the *Osterix* locus recombines *Cre* to the correct orientation in progenitors of osteoblasts and BMAds. However, because *Adipoq* is selectively expressed in adipocytes (Eguchi et al., 2011), *Cre* was expressed in BMAds, but not in osteoblasts or other adipose depots. Consistent with this schema, *Cre* in the correct orientation (flipped band, Figure 1—figure supplement 1A–C) was only observed in caudal vertebral DNA of mice that were positive for at least one copy each of *Osterix* (Mut band) and FAC (Ori band). The correct orientation of *Cre* (flipped band) was also observed in mRNA isolated from distal tibiae and caudal vertebrae, but not WAT depots, of *Osterix-FLPo* mice positive for FAC (Figure 1—figure supplement 1D). The correct insertion of the sequence in *Adipoq* 3'-UTR was validated by Sanger sequencing following genomic PCRs that spanned endogenous *Adipoq* sequences, homology arms, *IRES* and *Cre* (Figure 1—figure supplement 1E). To investigate the cell type specificity of *Cre* activity, we next bred BMAd-Cre mice to mT/mG reporter mice (Muzumdar et al., 2007; Figure 1E), in which all tissues and cells express red fluorescence (membrane-targeted tdTomato; mT) at baseline, and will express membrane-targeted EGFP in the presence of



**Figure 1.** Generation of a BMAd-specific Cre mouse model (BMAd-Cre). (A) Efficacy of *Osterix-FLPo* was evaluated by crossing with *FLPo*-dependent EGFP reporter to yield *Osterix-EGFP*. (B) *Osterix-EGFP* male mice at 16 weeks were sacrificed. Fresh tissue confocal microscopy was performed on bisected caudal vertebrae, distal tibia and proximal tibia. Red arrows indicate singly dispersed BMAds. Scale bar; 100  $\mu$ m. (C) Frozen-sections of proximal tibial slides from *Osterix-EGFP* were stained with Anti-GFP (green) and DAPI (blue). Scale bar; 50  $\mu$ m. (D) Schematic of how *Osterix-FLPo* recombines *FLPo*-activated *Adipoq-Cre* (FAC) in BMAd-Cre mice to restrict expression of *Cre* to BMAds. (E) BMAd-Cre mice were bred with mT/mG reporter mice and the resulting BMAd-mT/mG mice were sacrificed at 16 weeks of age. Cellular fluorescence was evaluated by fresh tissue confocal microscopy. Scale bar; 100  $\mu$ m. (F) Proximal tibial sections from BMAd-mT/mG mice were stained with antibodies to tdTomato (red) and EGFP (green), and nuclei were counterstained with DAPI (blue). \* indicates BMAds. Scale bar; 50  $\mu$ m.

The online version of this article includes the following source data and figure supplement(s) for figure 1:

**Figure supplement 1.** Genotyping strategy and validation of BMAd-Cre.

Figure 1 continued on next page

Figure 1 continued

**Figure supplement 2.** Insertion of *IRES-Cre* cassette in the 3'UTR of endogenous *Adipoq* decreases expression of adiponectin but does not cause a metabolic or bone phenotype.

**Figure supplement 2—source data 1.** Insertion of *IRES-Cre* cassette in the 3'UTR of endogenous *Adipoq* decreases expression of adiponectin but does not cause a metabolic or bone phenotype.

and number of FAC alleles. Indeed, Cre efficiency was ~80% in both male and female mice over 16 weeks of age with one Cre allele, and over 90% at 12 weeks of age in mice with two Cre alleles (**Figure 1—figure supplement 1I**).


Previous studies found that a randomly inserted *Adipoq-Cre* bacterial artificial chromosome (BAC) causes recombination in osteoblasts (**Bozec et al., 2013; Eguchi et al., 2011; Mukohira et al., 2019**); thus, we tested whether this observation is true in BMAd-Cre mice, which rely on endogenous *Adipoq* expression that is further restricted by *Osterix*. When BMAd-Cre mice were bred to mT/mG reporter mice, only tdTomato-positive cells were detectable on trabecular bone surfaces (**Figure 1F**), suggesting that osteoblasts were not targeted. However, labeling of a small subset of stromal/dendritic cells was consistently observed, likely due to expression of *Adipoq* within this cell population (**Mukohira et al., 2019**).

Although insertion of the FLPo-activated Cre cassette into the 3'-UTR of endogenous *Adipoq* overcomes potential problems that arise from random genomic integration, we considered the possibility that placement of the *IRES-Cre* cassette within the 3'-UTR might alter the expression and/or secretion of endogenous adiponectin. We found that insertion of the *IRES-Cre* cassette caused a small, non-significant decrease in *Adipoq* mRNA expression in whole caudal vertebrae or distal tibiae, whereas adiponectin mRNA in white adipose tissue was elevated by more than threefold (**Figure 1—figure supplement 2A**). Thus, the cassette itself did not limit expression of mRNA. Instead, it appeared that the 2 kb *IRES-Cre* cassette within the 3'-UTR impairs translatability of the mRNA since expression of adiponectin protein in WAT and BMAT was decreased by ~50% (**Figure 1—figure supplement 2B and C**). Circulating adiponectin concentrations were decreased even further (**Figure 1—figure supplement 2D–F**), suggesting that flux of translated adiponectin protein was impaired through the secretion pathway. Of note, hypoadiponectinemia is associated with insulin resistance (**Cook and Semple, 2010; Li et al., 2021**), with discrepant effects reported on osteogenesis (**Lewis et al., 2021**). Thus, we evaluated systemic metabolism in BMAd-Cre mice and found that body weight, glucose tolerance, WAT depot weights, and tibial trabecular and cortical bone variables were unaffected by this degree of hypoadiponectinemia (**Figure 1—figure supplement 2G–P**). To minimize variability between treatments, all mice used in the following studies were positive for both *Osterix-FLPo* (predominantly two alleles) and FAC (mostly two alleles). Gene knockout mice and their controls were determined by the presence or absence of floxed alleles, respectively.

## Ablation of adipose triglyceride lipase (ATGL, *Pnpla2*) causes BMAT expansion

A fundamental function of adipocytes is to store excess energy as triacylglycerols and to release non-esterified fatty acids (NEFA) and glycerol during times of negative energy balance. ATGL is the first and rate-limiting enzyme in the lipolytic process; thus, to determine the physiological functions of BMAd lipolysis in bone metabolism and hematopoiesis, we generated BMAd-*Pnpla2*<sup>-/-</sup> mice, in which the gene encoding ATGL, *Pnpla2*, was specifically deleted in BMAd. We validated the deletion of ATGL in caudal vertebrae, because cBMAT is abundant in this location. Mutant *Pnpla2* mRNA was observed in caudal vertebrae of BMAd-*Pnpla2* mice, but not in WAT (**Figure 2A**). Possible sources for the remaining wildtype (WT) *Pnpla2* signal include periosteal WAT, non-adipocyte cells, or perhaps from incomplete deletion of *Pnpla2* in BMAd. Immunofluorescent staining confirmed loss of ATGL in proximal tibial rBMAd of BMAd-*Pnpla2*<sup>-/-</sup> mice (**Figure 2B**). ATGL protein was reduced substantially

cell-specific Cre. We observed loss of tdTomato and gain of EGFP in BMAT depots of caudal vertebrae (tail) and tibiae, but not in brown or white adipose depots, or other tissues/organs such as liver, pancreas, muscle and spleen (**Figure 1E** and **Figure 1—figure supplement 1F**). To evaluate conditions optimal for Cre-induced recombination, we visualized conversion of tdTomato to EGFP in BMAd-Cre mice at various ages and with different FAC copy numbers (**Figure 1—figure supplement 1G–H**) and found that the proportion of EGFP-positive BMAd increased with age



**Figure 2.** Ablation of adipose triglyceride lipase (ATGL; gene name *Pnpla2*) increases size and number of BMAd. (A–J) Male mice of the indicated genotypes at 24 weeks of age were euthanized for investigation of white adipose tissue (WAT) and bone. (A) RNA was extracted from WAT and caudal vertebrae, and converted to cDNA. PCR products for wildtype (WT; 1257 bp) *Pnpla2* and exon 2–7 knockout (Mut; 553 bp) bands were visualized. (B) Decalcified proximal tibiae were sectioned and used for immunofluorescent staining for ATGL (green) expression. Slides were counterstained with DAPI (blue) for nuclei. Scale bar; 50  $\mu\text{m}$ . (C) Immunoblot analyses of ATGL,  $\alpha$ -tubulin, and ERK2 in lysates from subcutaneous WAT and caudal vertebral. (D–F) Decalcified tibiae were stained with osmium tetroxide and visualized by  $\mu\text{CT}$  (D). BMAT in proximal (E) and distal (F) tibia was quantified. Data are expressed as mean  $\pm$  SD. \* indicates  $p < 0.05$  with a two-sample t-test. (G–H) Decalcified tibiae were paraffin-sectioned and stained with Hematoxylin & Eosin. Representative pictures were taken from proximal (G) and distal (H) tibia. Scale bar; 200  $\mu\text{m}$ . (I–J) BMAd sizes from proximal (I) and distal (J) tibiae were quantified with MetaMorph software. Data are expressed as mean  $\pm$  SD. \* indicates  $p < 0.05$  with two-way ANOVA with Sidak’s multiple comparisons test. (K–M) Distal tibial BMAT was flushed from female BMAd-*Pnpla2*<sup>-/-</sup> and their wildtype littermates at 24 weeks of age. For each n, distal tibial explants from two mice were combined per well and cultured in 2% BSA-HBSS solution (K). Subgroups from each genotype were treated with forskolin (FSK, 5  $\mu\text{M}$ ) or vehicle (Veh, DMSO). Glycerol (L) and non-esterified fatty acid (NEFA; M) in culture media at indicated time points were measured by colorimetric assay (n=3–4 per treatment). \* indicates *Pnpla2*<sup>+/-</sup> (FSK) different from *Pnpla2*<sup>+/-</sup> (Veh) and from *Pnpla2*<sup>-/-</sup> (FSK) with  $p < 0.05$  with three-way ANOVA followed by Sidak’s multiple comparisons test.

The online version of this article includes the following source data for figure 2:

**Source data 1.** Ablation of adipose triglyceride lipase (ATGL; gene name *Pnpla2*) increases size and number of BMAd.

in caudal vertebrae, but not in subcutaneous WAT (Figure 2C), which further confirmed specificity of BMAd-Cre recombinase for BMAT.

To quantify effects of *Pnpla2*-deficiency on bone marrow adiposity and cellularity, we used osmium tetroxide, and hematoxylin and eosin staining, to evaluate BMAT quantity and cellular details, respectively. We found that BMAT volume was significantly increased in proximal tibiae and throughout the endocortical compartment of BMAd-*Pnpla2*<sup>-/-</sup> mice, whereas differences in BMAT volume were not observed in distal tibiae, which was almost completely occupied by BMAT in control mice (Figure 2D–F). Histological analyses revealed increased BMAd number in proximal tibiae of BMAd-*Pnpla2*<sup>-/-</sup> mice (Figure 2G and H). Depletion of *Pnpla2* also caused BMAd hypertrophy in both proximal and distal tibia, with an increased proportion of BMAd larger than 500  $\mu\text{m}^2$  observed in proximal tibia, and larger than 1000  $\mu\text{m}^2$  observed in distal tibia (Figure 2I and J). Secretion of basal glycerol


and NEFA from ex vivo cultured explants of distal tibial BMAT was not different between genotypes. On the other hand, forskolin treatment greatly increased lipolysis in BMAT explants from control mice, but secretion of glycerol and NEFA from BMAd-*Pnpla2*<sup>-/-</sup> explants remained unchanged from basal rates (**Figure 2K–M**). These results confirm that BMAd of BMAd-*Pnpla2*<sup>-/-</sup> mice have impaired lipolysis.

## BMAd lipolysis is required to maintain bone homeostasis in male mice under conditions of CR, but not when mice are fed ad libitum

We next evaluated whether loss of BMAd lipolysis in male BMAd-*Pnpla2*<sup>-/-</sup> mice is sufficient to influence systemic physiology, or function of bone cells within the marrow niche. In mice fed normal chow ad libitum, we did not observe differences in body weight, glucose tolerance, or weights of soft tissue, including subcutaneous WAT (sWAT), epididymal WAT (eWAT), and liver (**Figure 3—figure supplement 1A–E**), which further confirmed the tissue-specificity of our BMAd-*Pnpla2* knockout model. As observed above, *Pnpla2* deficiency caused expansion of proximal tibial rBMAT (**Figure 3—figure supplement 1F and G**). Interestingly, when dietary energy was readily available, trabecular bone volume fraction, bone mineral density and trabecular number tended to be lower in BMAd-*Pnpla2*<sup>-/-</sup> mice, but statistical differences were not observed (**Figure 3A–C**).

Our experiments in ad libitum fed mice suggest that energy released from BMAd is dispensable for bone cell functioning when dietary energy is plentiful, which is supported by the comparable concentrations of glycerol and NEFA in circulation and in bone marrow supernatant in BMAd-*Pnpla2*<sup>+/+</sup> and BMAd-*Pnpla2*<sup>-/-</sup> mice (**Figure 3—figure supplement 1H and I**). To determine whether male BMAd-*Pnpla2*<sup>-/-</sup> mice have impaired bone homeostasis when dietary energy is limited, we next challenged mice with a 30% CR for 6 weeks. BMAd-*Pnpla2*<sup>-/-</sup> mice did not have altered body weight, glucose tolerance, or tissue weights comparing with their controls (**Figure 3—figure supplement 1J–N**), suggesting that BMAd were not a critical source of circulating energy under these conditions. Although *Pnpla2*<sup>-/-</sup> mice fed ad libitum had increased rBMAT compared to controls (**Figure 3—figure supplement 1F and G**), CR stimulated rBMAT expansion in control mice such that BMAT volume and BMAd size were comparable between genotypes (**Figure 3—figure supplement 1O–S**). Despite having a similar amount of rBMAT, BMAd-*Pnpla2*<sup>-/-</sup> mice fed CR diet had reduced trabecular bone volume fraction, connective density, and bone mineral density when compared to controls (**Figure 3D and E**). This reduction in bone mass is due to decreased trabecular bone number and increased trabecular spacing, without effects on trabecular thickness (**Figure 3F**). BMAd are a source of NEFA for vicinal osteoblasts (*Maridas et al., 2019*); thus, the reduction in trabecular bone in CR BMAd-*Pnpla2*<sup>-/-</sup> mice likely resulted from impaired osteoblast function due to insufficient energy available in the bone marrow niche. Consistent with this notion, we observed a trend ( $p=0.07$ ) towards reduced NEFA concentrations in bone marrow supernatant of CR BMAd-*Pnpla2*<sup>-/-</sup> mice, whilst circulating glycerol and NEFA concentrations were not different between genotypes (**Figure 3—figure supplement 1T and U**). Although FAC mice have hypoadiponectinemia at baseline, circulating adiponectin was still increased dramatically in response to CR. Comparable adiponectin concentrations between BMAd-*Pnpla2*<sup>+/+</sup> and BMAd-*Pnpla2*<sup>-/-</sup> mice (**Figure 3—figure supplement 1V**) excludes the possibility that differences in circulating adiponectin may confound the bone phenotype in BMAd-*Pnpla2*<sup>-/-</sup> mice. Finally, changes in cortical bone area and thickness were not observed in BMAd-*Pnpla2*<sup>-/-</sup> mice with either ad libitum or CR diet (**Figure 3—figure supplement 2A–D**), perhaps because cortical bone surfaces are less active.

To investigate mechanisms underlying trabecular bone loss in CR BMAd-*Pnpla2*<sup>-/-</sup> mice, we next measured circulating markers of bone cell activity and performed histomorphometry. Osteoblast and osteoclast numbers and osteoclast surface were not changed by BMAd-*Pnpla2* deficiency under ad libitum conditions (**Figure 3—figure supplement 2E and F**). Although circulating markers of bone formation (P1NP) and osteoclast activation (RANK Ligand) were not altered in BMAd-*Pnpla2*<sup>-/-</sup> mice, markers for bone resorption (CTX-1) and osteoclast activation (TRACP5b) were decreased or showed a strong trend towards reduction, respectively (**Figure 3—figure supplement 2G–J**). Although with CR, osteoblast numbers were not altered by a deficiency of BMAT lipolysis, the bone formation marker P1NP was decreased (**Figure 3G and I**), suggesting that osteoblast functions were impaired. Osteoclast numbers were increased in CR BMAd-*Pnpla2*<sup>-/-</sup> mice, but the osteoclast surface per bone



**Figure 3.** BMA*d* lipolysis is required to maintain bone homeostasis in male mice under CR conditions, but not when mice are fed ad libitum. **(A-C)** Male BMA*d*-*Pnpla2*<sup>-/-</sup> and their BMA*d*-*Pnpla2*<sup>+/+</sup> littermates with ad libitum feeding were euthanized at 24 weeks of age. Two independent age- and sex- matched cohorts were plotted together. Tibiae from ad libitum mice were analyzed by  $\mu$ CT for indicated trabecular (Tb.) bone variables. BV/TV: bone volume fraction; Conn. Dens: connective density; BMD: bone mineral density; N: number; Th: thickness; Sp: separation. Scale bars indicate 500  $\mu$ m. **(D-M)** Male mice at 18 weeks of age underwent 30% CR for 6 weeks. Two independent age- and sex- matched cohorts were plotted together for  $\mu$ CT parameters **(D-F)**, one of those two cohorts was used for ELISA, and static or dynamic histomorphometry **(G-M)**. **(D-F)** Tibiae from CR mice were analyzed by  $\mu$ CT for indicated trabecular bone variables. Scale bar, 500  $\mu$ m. **(G-H)** Static histomorphometry analyses were performed to calculate osteoblast number (Ob. N), osteoclast number (Oc. N) and osteoclast surface (Oc. S) per bone surface (BS). **(I-J)** Concentrations of circulating P1NP and TRACP5b in CR mice were measured. **(K)** Osteoid quantification was performed on undecalcified plastic sections with Goldner's Trichrome staining. **(L-M)** Dynamic histomorphometry was performed on calcein-labelled trabecular bone from proximal tibia. sLS: single-labelled surface; MS: mineralized surface; Ir.L.Wi: inter-label width; MAR: mineral apposition rate. Data are expressed as mean  $\pm$  SD. \* indicates  $p < 0.05$  with a two-sample t-test. In addition, multiple unpaired t tests had been performed crossing all parameters, p values were adjusted for multiple comparisons using Two-stage step-up (Benjamini, Krieger, and Yekutieli) with FDR method. Adjusted p values are shown in **Figure 3—source data 1**.

Figure 3 continued on next page

Figure 3 continued

The online version of this article includes the following source data and figure supplement(s) for figure 3:

**Source data 1.** BMAd lipolysis is required to maintain bone homeostasis in male mice under CR conditions, but not when mice are fed ad libitum.

**Figure supplement 1.** Blocking BMAd-lipolysis does not influence global metabolism when mice are fed ad libitum or calorically restricted.

**Figure supplement 1—source data 1.** Blocking BMAd-lipolysis does not influence global metabolism when mice are fed ad libitum or calorically restricted.

**Figure supplement 2.** Cortical bone variables in BMAd-*Pnpla2*<sup>-/-</sup> mice and other possible mechanisms for bone loss in BMAd-*Pnpla2*<sup>-/-</sup> CR mice.

**Figure supplement 2—source data 1.** Cortical bone variables in BMAd-*Pnpla2*<sup>-/-</sup> mice and other possible mechanisms for bone loss in BMAd-*Pnpla2*<sup>-/-</sup> CR mice.

**Figure supplement 3.** BMAd lipolysis is not required in female mice to maintain bone homeostasis under CR conditions.

**Figure supplement 3—source data 1.** BMAd lipolysis is not required in female mice to maintain bone homeostasis under CR conditions.

**Figure supplement 4.** BMAd-lipolysis impairment in estrogen-deficient female mice does not affect CR-induced bone changes.

**Figure supplement 4—source data 1.** BMAd-lipolysis impairment in estrogen-deficient female mice does not affect CR-induced bone changes.

---

surface (Oc.S/BS) was not changed and the osteoclast activation marker, TRACP5b, was decreased (**Figure 3H and J**), suggesting osteoclast function was inhibited. No differences were observed in RANK Ligand and CTX-1 with CR (**Figure 3—figure supplement 2K and L**). We then visualized and quantified osteoid thickness with Goldner's trichrome staining and observed a trend towards thinner osteoid layers without affecting osteoid surface (**Figure 3K and Figure 3—figure supplement 2M**), which could be secondary to impaired secretion of collagen matrix by osteoblasts or to enhanced bone mineralization. Further, we injected mice with calcein to label those bone surfaces undergoing active mineralization. Dynamic histomorphometry data suggests that BMAd-*Pnpla2*<sup>-/-</sup> mice had less bone-forming surface, as indicated by reduced single-labelled surface (sLS) and mineral surface (MS) (**Figure 3L**). There were no differences in double-labelled bone surface, inter-label width, mineral apposition rate or osteoid maturation time (**Figure 3M and Figure 3—figure supplement 2N**), suggesting that bone mineralization is not affected by loss of BMAd lipolysis. Taken together, these data support a model in which reduced trabecular bone in BMAd-*Pnpla2*<sup>-/-</sup> mice is likely due to impaired ability of osteoblasts to secrete osteoid.

## BMAd lipolysis is not required to maintain bone homeostasis under calorie-restricted conditions in female mice

To determine whether sex influences responses of BMAd-*Pnpla2*<sup>-/-</sup> mice to CR, we performed similar experiments in female mice at 20 weeks of age. As expected, after six weeks of CR, both control and knockout mice exhibited comparable reduced body weights, random blood glucose concentrations, and tissue weights (**Figure 3—figure supplement 3A and B**). CR or *Pnpla2* deficiency caused expansion of proximal tibial rBMAT, which was further increased in CR BMAd-*Pnpla2*<sup>-/-</sup> mice (**Figure 3—figure supplement 3C**). Whereas CR increased trabecular bone BV/TV, and decreased Tb.Sp, BMAd *Pnpla2* deletion did not cause changes in trabecular or cortical bone variables in female mice (**Figure 3—figure supplement 3D and E**). In addition, complete blood cell analyses did not reveal substantial differences in white or red blood cell populations influenced by diet or genotype (**Figure 3—figure supplement 3F**).

We next considered whether estrogen protects female mice from CR-induced osteoporosis. Thus, we ovariectomized control and BMAd-*Pnpla2*<sup>-/-</sup> mice 2 weeks prior to initiation of CR. Following initiation of CR, both control and knockout mice demonstrated rapid reduction in body weight for 2 weeks, then gradually stabilized during the following ten weeks (**Figure 3—figure supplement 4A**). We did not observe significant differences in glucose tolerance or bone length with CR or *Pnpla2* deletion (**Figure 3—figure supplement 4B and C**). Although CR caused reduction in WAT and spleen weights,



these variables were generally not different between genotypes (**Figure 3—figure supplement 4D**). Interestingly, despite the dramatic increases of BMAT with CR or BMAd-*Pnpla2* deficiency, OVX-associated trabecular bone loss was partially eliminated by CR treatment, which was evidenced by a relative increase in bone volume fraction (Tb. BV/TV) and trabecular number (Tb. N) (**Figure 3—figure supplement 4E and F**). These data suggest that the metabolic benefits of CR diet may combat detrimental effects of estrogen deficiency and/or aging. Although not observed in intact mice, with OVX *Pnpla2*-deficient mice, the loss of BMAd ATGL caused a slight reduction in trabecular bone mineral density (Tb. BMD) and thickness (Tb. Th) compared to OVX controls (revealed by two-way ANOVA analysis) (**Figure 3—figure supplement 4F**).


### BMAd lipolytic deficiency impairs myelopoiesis during regeneration

A single rBMAd connects to almost 100 hematopoietic cells (*Robles et al., 2019*), suggesting that BMAds potentially serve as important local energy sources for hematopoiesis. However, when fed ad libitum, male BMAd-*Pnpla2*<sup>-/-</sup> mice did not exhibit differences in mature blood cells populations, as assessed by complete blood cell counts (**Supplementary file 1**) or in bone marrow hematopoietic cell populations, as assessed by flow cytometry (**Supplementary file 2** and **Figure 4—figure supplement 1A and B**). However, we did observe a reduced percentage of bone marrow mature neutrophils in CR BMAd-*Pnpla2*<sup>-/-</sup> mice (**Supplementary file 1, Supplementary file 2**), perhaps due to impaired maturation of granulocytes. These data suggest that although neutrophil defects were observed in CR BMAd-*Pnpla2*<sup>-/-</sup> mice, other hematopoietic cell populations can metabolically compensate for the lack of BMAd lipolytic products.

To investigate further whether hematopoiesis is dependent upon BMAd lipolysis, we administered a sublethal dose of whole-body irradiation, and evaluated hematopoietic cell recovery. Following irradiation, white and red blood cell depletion and recovery were monitored by complete blood cell counts every 2–3 days (**Figure 4—figure supplement 1C–E**). During the recovery phase, three-way ANOVA analyses revealed that differences in time (days) and diet (AL vs CR) were observed for total white blood cells, lymphocytes, and red blood cells, while significant interactions between genotype (BMAd-*Pnpla2*<sup>+/+</sup> vs BMAd-*Pnpla2*<sup>-/-</sup>) and time were observed for neutrophils, eosinophils and basophils, suggesting BMAd-*Pnpla2* deficiency specifically influenced myeloid lineage cells. Nine days after irradiation, HSPCs (**Figure 4—figure supplement 1F and G**) and mature/immature hematopoietic cells (**Figure 4A–H**) were not influenced by deficiency of BMAd-lipolysis in ad libitum fed mice. However, CR decreased bone marrow cellularity (BMNC) (**Figure 4A**), and most HSPC populations in control mice (**Figure 4—figure supplement 1F and G**). Two-way ANOVA also revealed inhibitory effects of CR on monocytes and neutrophils, without changes to lymphocytes (**Figure 4B–E**). In BMAd-*Pnpla2*<sup>-/-</sup> mice, HSPCs were not altered by CR except for PreMegE cells, which were suppressed. Bone marrow cellularity, monocytes, and neutrophils were also decreased in CR BMAd-*Pnpla2*<sup>-/-</sup> mice. The recovery of neutrophils, preneutrophils, immature and mature neutrophils following irradiation was impaired by CR, and *Pnpla2*-deficiency further reduced ability of neutrophils and mature neutrophils to regenerate (**Figure 4E–H**). These reductions in monocytes and neutrophils in CR BMAd-*Pnpla2*<sup>-/-</sup> mice suggest that BMAd-lipolysis is required for myeloid cell lineage regeneration when energy supply from circulation is limited. CFU assays, which were optimized for the growth of myeloid progenitor cells (CFU-Granulocytes, CFU-Macrophages and CFU-GM), demonstrated a trend towards fewer granulocyte progenitor colonies (CFU-G) from CR BMAd-*Pnpla2*<sup>-/-</sup> mice (**Figure 4I**). The proliferative capacity of macrophage progenitors (CFU-M) was impaired when derived from BMAd-*Pnpla2*<sup>-/-</sup> mice fed ad libitum, or when derived from CR mice of either genotype (**Figure 4J**). CR marrow produced fewer granulocyte-macrophage progenitors (CFU-GM), which was further reduced when isolated from mice with impaired BMAd-lipolysis (**Figure 4K**). These data suggest that proliferative and differentiation capacities of cultured myeloid cell progenitors may have been reprogrammed in the marrow niche when their energy supply was limited either by CR or impaired BMAd lipolysis (**Figure 4L**).

### Coupling of BMAd *Pnpla2* deletion and CR results in extensive alterations to the bone marrow transcriptome

To determine mechanisms by which BMAd *Pnpla2* deficiency causes bone loss in CR male mice, we profiled overall gene expression using bulk RNA sequencing (RNAseq) in bone marrow plugs from distal tibiae, a skeletal location highly enriched with BMAT. PCA plots showed that RNA profiles from



**Figure 4.** BMAd-*Pnpla2* deficiency impairs myelopoiesis. (A-H) BMAd-*Pnpla2*<sup>-/-</sup> mice and littermate controls (*Pnpla2*<sup>+/+</sup>) were caloric restricted (CR; +) for 20 weeks or remained on an ad libitum diet (-), and then received whole-body irradiation (6 Gy). Mice were euthanized 9 days post-irradiation. Femurs were collected for flow cytometry to measure the regeneration of hematopoietic cells. Bone marrow mononuclear cells (BMNCs), monocytes, B and T lymphocytes and neutrophils were quantified. (I-L) CFU assays. Femora and tibial bone marrow cells were isolated from BMAd-*Pnpla2*<sup>-/-</sup> mice and littermate controls (*Pnpla2*<sup>+/+</sup>), which had been fed ad libitum (-) or a caloric restricted (CR; +) diet for 20 weeks. After counting,  $1 \times 10^4$  cells were plated for CFU assays. Colonies were counted by an independent expert in a blinded manner 7 days after plating. Data are expressed as mean  $\pm$  SD. \* indicates  $p < 0.05$  with two-way ANOVA analyses followed by Šidák's multiple comparisons test. Significant effects of genotype, diet, or their interactions are shown, as are trends.


The online version of this article includes the following source data and figure supplement(s) for figure 4:

**Source data 1.** BMAd-*Pnpla2* deficiency impairs myelopoiesis.

**Figure supplement 1.** Flow cytometry strategies for hematopoietic cells and sublethal irradiation-induced hematopoietic regeneration in BMAd-*Pnpla2*<sup>-/-</sup> mice.

**Figure supplement 1—source data 1.** Flow cytometry strategies for hematopoietic cells and sublethal irradiation-induced hematopoietic regeneration in BMAd-*Pnpla2*<sup>-/-</sup> mice.

CR groups were distinct from ad libitum controls (**Figure 5—figure supplement 1A**). Whereas *Pnpla2* deficiency did not cause gene expression to diverge substantially in mice fed ad libitum, loss of *Pnpla2* interacted with CR to cause a well-segregated pattern of gene expression (**Figure 5—figure supplement 1A**). By our criteria ( $\text{padj} < 0.05$ ,  $|\log_2 \text{fold change}| > 1$ ), CR changed expression of 1026 genes compared to ad libitum controls (left). Although *Pnpla2* deficiency alone only altered 10 genes in BMAd-*Pnpla2*<sup>-/-</sup> mice fed ad libitum (middle), loss of *Pnpla2* in CR mice caused alterations in 1060 genes (right) (**Figure 5—figure supplement 1B**). Analyses of genes regulated in BMAd-*Pnpla2*<sup>+/+</sup> mice with CR revealed four distinct clusters (**Figure 5A**). Approximately 80% of genes fell in cluster 1, which contained genes upregulated by CR in control mice, with induction largely blocked by *Pnpla2*



**Figure 5.** BMAd-Pnpla2 deficiency causes extensive alterations to the bone marrow transcriptome only when coupled with CR. Male control and BMAd-Pnpla2<sup>-/-</sup> mice at 24 weeks of age were either fed AL or underwent 30% CR for 6 weeks. Distal tibial cBMAT was flushed and cBMAT from two mice was pooled as one sample for RNAseq analyses (n of 3 or 4 per treatment). **(A)** Differential genes with our criteria (padj < 0.05 and |Log<sub>2</sub> fold change| > 1) between BMAd-Pnpla2<sup>+/+</sup> CR and BMAd-Pnpla2<sup>+/+</sup> ad libitum (AL) were grouped into 4 clusters. **(B)** Genes different between BMAd-Pnpla2<sup>+/+</sup> CR and BMAd-Pnpla2<sup>+/+</sup> AL were ordered from maximum to minimum log<sub>2</sub> fold change (red dots), and compared to corresponding data from BMAd-Pnpla2<sup>-/-</sup> CR versus BMAd-Pnpla2<sup>-/-</sup> AL (blue dots). Venn diagram shows the differential genes between BMAd-Pnpla2<sup>+/+</sup> CR versus BMAd-Pnpla2<sup>+/+</sup> AL BMAT; and BMAd-Pnpla2<sup>-/-</sup> CR versus BMAd-Pnpla2<sup>-/-</sup> AL BMAT. **(C)** Pathway analyses of genes significantly changed by CR in BMAd-Pnpla2<sup>+/+</sup> mice, but not in CR mice lacking Pnpla2 (indicated by \* area in panel B). Pathways further analyzed by heatmap indicated with blue arrows. **(D-F)** Expression Z-scores of genes related to adipogenesis **(D)**, skeletal system development **(E)** and extracellular matrix organization **(F)** were shown as heatmap. Effects of genotype and diet, and their interactions were analyzed by three-way ANOVA.

The online version of this article includes the following source data and figure supplement(s) for figure 5:

**Source data 1.** BMAd-Pnpla2 deficiency causes extensive alterations to the bone marrow transcriptome only when coupled with CR.

**Figure supplement 1.** CR causes profound changes in BMAT transcriptome.

Figure 5 continued on next page

Figure 5 continued

**Figure supplement 2.** BMAAd-*Pnpla2* deficiency causes extensive alterations to the bone marrow transcriptome only when coupled with CR.

**Figure supplement 2—source data 1.** BMAAd-*Pnpla2* deficiency causes extensive alterations to the bone marrow transcriptome only when coupled with CR.

**Figure supplement 3.** BMAAd-*Pnpla2* deficiency alters gene expression in response to CR.

deficiency in CR mice. Pathway analyses of cluster 1 with Metascape (<https://metascape.org>) revealed that regulated genes were associated with vasculature development and cellular response to growth factor stimulus, which likely reflects adaptation mechanisms to compensate for energy insufficiency (**Figure 5—figure supplement 1C**). In addition, genes associated with skeletal system development, extracellular matrix organization, and adipogenesis pathways were upregulated by CR in control mice, but these effects were blunted by *Pnpla2* deletion (**Figure 5—figure supplement 1C**). Cluster 2 includes genes that were mildly upregulated by CR in control mice and were further increased with *Pnpla2*-deficiency. Although no specific pathways were enriched in this gene set, upregulation of two monocarboxylate transporters, *Slc16a11* and *Slc16a4*, suggests a potential mechanism for fueling cellular metabolism, and perhaps for the energy source underlying expansion of BMAAd with CR and BMAAd *Pnpla2* deletion (**Figure 5—figure supplement 1D**). Cluster 3 highlighted genes that were downregulated by CR treatment regardless of genotype (**Figure 5—figure supplement 1E**), and that were associated with B cell proliferation and interleukin-8 production, which may partially explain changes in hematopoietic cellularity. Cluster 4 contained 80 genes that were down-regulated independently by CR and *Pnpla2*-deficiency, and were associated with regulation of ossification and calcium-mediated signaling (**Figure 5—figure supplement 1F**).

To evaluate further whether BMAAd-*Pnpla2* is required for the adaptation of BMAT to CR, we graphically ordered genes from those maximally induced to those most repressed by CR in control mice (**Figure 5B**; red dots). Of these genes, 66% did not meet our criteria for regulated expression by CR in BMAAd-*Pnpla2*<sup>-/-</sup> mice (blue dots). Pathway analyses on the 34% of genes regulated by CR regardless of *Pnpla2* deficiency revealed association with ribonuclease activity, response to hormones and other transmembrane signaling pathways (**Figure 5—figure supplement 2A**). Pathway analyses of genes for which *Pnpla2* is required for response to CR identified vasculature development and cellular response to growth factor stimulus, similar to cluster 1, followed closely by skeletal system development, adipogenesis genes, and extracellular matrix organization pathways (**Figure 5C**). A heatmap showed that the adipogenic genes, including *Adipoq*, *Fabp4*, *Cebpa*, *Lipe*, *Lpl*, *Ppara*, *Pparg*, *Scd1*, *Plin1*, *Cd36*, *Fasn*, and *Acaca*, were upregulated by CR in control mice (**Figure 5D**), a subset of which were confirmed by qPCR (**Figure 5—figure supplement 2B**). These changes may help to explain molecular mechanisms underlying BMAT expansion following CR. It is important to note that whereas CR BMAAd-*Pnpla2*<sup>+/+</sup> and BMAAd-*Pnpla2*<sup>-/-</sup> mice had comparable amounts of BMAT (**Figure 3—figure supplement 1O and P**), adipocyte gene expression was greatly suppressed in mice with BMAT lacking *Pnpla2* (**Figure 5D**). This observation is consistent with prior work showing that adipocyte-specific deletion of *Pnpla2* results in decreased expression of genes associated with lipid uptake, synthesis, and adipogenesis (Schoiswohl et al., 2015), perhaps because NEFA and associated metabolites act as PPAR ligands (Mottillo et al., 2012). In addition, genes related to endogenous fatty acid biosynthesis were also increased by CR in BMAAd-*Pnpla2*<sup>+/+</sup> mice, but not in mice lacking *Pnpla2* (**Figure 5—figure supplement 2C**). Interestingly, myeloid leukocyte differentiation genes followed a similar pattern (**Figure 5—figure supplement 2D**), which may contribute to the reduced neutrophil production and impaired myeloid cell proliferation of CR BMAAd-*Pnpla2*<sup>-/-</sup> mice (**Supplementary file 1, Supplementary file 2, and Figure 4**).

We previously observed increased bone loss in BMAAd-*Pnpla2*<sup>-/-</sup> mice challenged with CR (**Figure 3**). To investigate potential mechanisms underlying this bone loss, we analyzed pathways from Cluster 1 related to bone metabolism, skeletal system development and extracellular matrix organization. Interestingly, osteoblast-derived alkaline phosphatase (*Alpl*), *Col1a1* and *Col1a2*, and bone marrow Fgf/Fgfr and Wnt signaling-related molecules were highly induced by CR in control mice but not in *Pnpla2*-deficient mice (**Figure 5E**); many of these genes are also found in the ossification pathway. Multiple collagen genes, *Lox*, and *Adamts* (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family members, which are multidomain extracellular protease enzymes and play key roles in extracellular matrix remodeling, were also upregulated by CR in control mice, with effects largely eliminated

by *Pnpla2* deficiency (**Figure 5F**). These findings may partially explain why osteoid thickness tended to be thinner in BMAd-*Pnpla2*<sup>-/-</sup> mice (**Figure 3K**). In this regard, 20 collagen genes were significantly up-regulated in control mice following CR (**Figure 5—figure supplement 2E**), whereas only four collagen genes were elevated in CR BMAd-*Pnpla2*<sup>-/-</sup> mice. Taken together, these data suggest that under conditions of limited dietary energy, BMAd provides energy to maintain osteoblast functions, including the secretion of collagen matrix for osteoid synthesis.


As mentioned above, loss of *Pnpla2* in CR mice altered expression of 1060 genes (**Figure 5—figure supplement 1B**; right), which were clustered into three groups (**Figure 5—figure supplement 3A**). Cluster 1 included genes that were induced only in CR BMAd-*Pnpla2*<sup>-/-</sup> mice. Although not localized to specific pathways, these genes were involved in diverse metabolic and cellular processes (e.g. *Perm1*, *mt-Nd6*, and *B3gat2*), and were generally expressed at low levels at baseline. In contrast, cluster 2 contained genes that were suppressed in CR BMAd-*Pnpla2*<sup>-/-</sup> mice, including pathways related to mitochondrial functions, hematopoietic progenitor cell differentiation, positive regulation of osteoblast differentiation and fatty acid biosynthetic process (**Figure 5—figure supplement 3B and C**), which sheds further light on the impaired HSPC proliferative capacity and osteoblast functions. Genes in cluster 3 were upregulated by CR, but not by CR in the absence of BMAd-*Pnpla2*. Pathway analyses highlighted the regulation of lipid catabolic process, triacylglyceride synthesis and leukocyte migration (**Figure 5—figure supplement 3D and E**), consistent with the impaired lipid metabolism and leukocyte production observed in BMAd-*Pnpla2*<sup>-/-</sup> mice.

### BMAd lipolysis is required for trabecular and cortical bone regeneration

To test whether BMAd is a critical source of local energy under conditions where energy needs are elevated, we investigated the impact of CR and BMAd *Pnpla2* deficiency on bone regeneration. To do this, we created a 0.7 mm hole in the proximal tibia, approximately 1–2 mm distal from the growth plate, and evaluated the newly formed woven bone in both the trabecular (endocortical) and cortical compartments nine days later (**Figure 6A**). As expected, CR impaired formation of bone in the trabecular (endocortical) region of interest (ROI), resulting in decreased bone volume fraction, mineral density, and mineral content (**Figure 6B**). Importantly, these effects of CR were mimicked by BMAd-specific *Pnpla2* deletion; however, gene deletion did not compound effects of CR on impaired bone regeneration, perhaps because newly-formed bone volume was already low with either CR or *Pnpla2* deficiency alone. We then visualized newly formed bone in the cortical bone compartment with Safranin O/ Fast Green (SO/FG) staining of paraffin-embedded proximal tibia sections (**Figure 6C**). Of note, both bone marrow stromal and periosteal cells contribute to the cortical bone regeneration and are derived from common mesenchymal progenitors (*Duchamp de Lageneste et al., 2018*). Although deficiency of BMAd-lipolysis is unlikely to affect periosteal cell functions when the cortical bone is intact, it may interact with this cell population during bone regeneration. CR also impaired formation of new woven bone in the cortical compartment by decreasing bone volume fraction, mineral density, and mineral content. As with bone formation in the trabecular compartment, effects of CR on the cortical compartment are mimicked by BMAd-specific depletion of *Pnpla2*, and effects of impaired BMAd lipolysis did not exacerbate CR-induced impaired bone regeneration (**Figure 6D**). Taken together, these data provide compelling evidence that under conditions where energy requirements are high, BMAd provides a critical local energy source for early-stage bone regeneration.

### Energy from BMAd protects against bone loss caused by chronic cold exposure

Cold exposure is well-documented to increase energy expenditure and adaptive thermogenesis, largely fueled by energy stored in WAT depots. To explore further under what conditions BMAd lipolysis may be critical for bone cell functions, we first evaluated female control and BMAd-*Pnpla2*<sup>-/-</sup> mice, which have higher content of BMAT than males, and housed them at room (22 °C) or cold (4 °C) temperatures for three weeks when they were at 20 weeks of age. As expected (*Scheller et al., 2015; Scheller et al., 2019*), cold exposure resulted in smaller rBMAd within the proximal tibia of BMAd-*Pnpla2*<sup>+/+</sup> mice (**Figure 6E and F**). In contrast, rBMAd size was increased at baseline in BMAd-*Pnpla2*<sup>-/-</sup> mice, with no reduction observed with cold exposure (**Figure 6E and G**). These data indicate that intact BMAd lipolysis was required for reduction of BMAd size with cold exposure. We then



**Figure 6.** Energy from BMAd is required for trabecular bone regeneration and protects against bone loss caused by chronic cold exposure. (A–D) BMAd-*Pnpla2*<sup>+/+</sup> and BMAd-*Pnpla2*<sup>-/-</sup> male mice at 24 weeks of age fed with chow diet (-) or underwent 30% CR for six weeks (+). A 0.7 mm proximal tibial defect was created 1–2 mm distal to the growth plate. Tibiae were collected 9 days after surgery. MicroCT was performed to analyze trabecular (endocortical) and cortical bone regeneration. (A) Representative analyzing images of bone defect. Example of  $\mu$ CT showing trabecular (endocortical) region of interest (ROI); green and cortical ROI (yellow). Newly generated woven bone in trabecular (endocortical; red) and cortical compartment (purple) is indicated. (B) Quantification of regenerated bone in the endocortical compartment - bone volume fraction (BV/TV), mineral density (BMD) and mineral content (BMC). Data are expressed as mean  $\pm$  SD. (C) Safranin O/ Fast Green (SO/FG) staining of new cortical compartment formation in defect sites. Scale bar; 200  $\mu$ m. (D) Quantification of regenerated cortical woven bone volume fraction (BV/TV), mineral density (BMD) and mineral content (BMC). (E–I) Female BMAd-*Pnpla2*<sup>+/+</sup> and BMAd-*Pnpla2*<sup>-/-</sup> mice at 20 weeks of age were singly housed at 4°C for three weeks without enrichments. (E) Proximal tibiae were decalcified and paraffin-sectioned for H&E staining. Representative images for proximal tibia are shown. Scale bar, 100  $\mu$ m. (F–G) Quantification of BMAds from H&E-stained slides using MetaMorph software. Comparison of BMAd size at room temperature (RT) versus cold exposure (CE) in mice of indicated genotypes. (H) Trabecular bone volume fraction (BV/TV) and mineral density (BMD) were quantified by  $\mu$ CT. Data are expressed as mean  $\pm$  SD. \* indicates  $p<0.05$  with two-way ANOVA analyses followed by Šidák's multiple comparisons test. Significant effects of genotype, diet, or their interactions are shown, as are trends.

Figure 6 continued on next page

Figure 6 continued

The online version of this article includes the following source data and figure supplement(s) for figure 6:

**Source data 1.** Energy from BMAd is required for trabecular bone regeneration and protects against bone loss caused by chronic cold exposure.

**Figure supplement 1.** Energy from BMAd protects against changes in trabecular microstructures caused by chronic cold exposure.

**Figure supplement 1—source data 1.** Energy from BMAd protects against changes in trabecular microstructures caused by chronic cold exposure.

evaluated bone mass by  $\mu$ CT and found that whereas trabecular bone of the proximal tibia was maintained in BMAd-*Pnpla2*<sup>+/+</sup> mice with cold stress, trabecular bone volume fraction declined with cold exposure in BMAd-*Pnpla2*<sup>-/-</sup> mice and bone mineral density showed a similar trend (**Figure 6H**). These results suggest that lipolysis from vicinal BMAds is important for maintenance of bone when energy needs are high or when energy supply is limited. Histomorphometry analyses did not reveal significant changes in osteoblast and osteoclast numbers, or in TRAP-positive osteoclast surface per bone surface (**Figure 6—figure supplement 1A–C**). However, the bone formation marker, P1NP, decreased in cold-exposed BMAd-*Pnpla2*<sup>-/-</sup> mice compared to room temperature controls (**Figure 6—figure supplement 1D**), suggesting that osteoblast functions were impaired.

We also evaluated whether BMAT lipolysis is necessary for maintenance of trabecular bone microstructures in male mice under cold exposure conditions (**Figure 6—figure supplement 1E–J**). Interestingly, control BMAd-*Pnpla2*<sup>+/+</sup> male mice were more vulnerable to cold-induced bone loss than female mice, with significant reductions of trabecular bone volume fraction, mineral density, and thickness. There was no obvious further decrease of these parameters in BMAd-*Pnpla2*<sup>-/-</sup> mice, perhaps because bone volume was already low with cold exposure. However, two-way ANOVA analyses revealed there were interactions between temperature and genotype, suggesting there were further changes in BMAd-*Pnpla2*<sup>-/-</sup> mice (**Figure 6—figure supplement 1E,F,H**). Although cold stimuli did not affect the microstructure parameters of trabecular bone in BMAd-*Pnpla2*<sup>+/+</sup> mice, cold exposure decreased trabecular connective density and trabecular number, and increased trabecular bone spacing in BMAd-*Pnpla2*<sup>-/-</sup> mice (**Figure 6—figure supplement 1G,I,J** and ). Taken together, these data highlight sexual dimorphism in the response of bone to cold, and that in both males and females, a further loss of bone is observed when BMAT lipolysis is impaired.

## Discussion

In the current study, we developed and tested for the first time, a BMAd-specific mouse model to more clearly understand the function of bone marrow adipose tissue, particularly during times of nutritional, hormonal, mechanical and environmental stress. Previously, the role of BMAds in the marrow niche was deduced through indirect inferences from associations of skeletal and hematopoietic phenotypes with bone marrow adipose tissue volume. This has been exemplified by a number of BMAT depletion models which showed high bone mass, including A-ZIP (*Naveiras et al., 2009*), *Adipoq*-driven DTA (*Zou et al., 2019*), and *Adipoq*-driven loss of *Pparg* (*Wang et al., 2013*), *Lmna* (*Corsa et al., 2021*), or *Bscl2* (*McIlroy et al., 2018*); however these lipodystrophic mice also lacked white and brown adipose depots and thus exhibit global metabolic dysfunction, including fatty liver, hyperlipidemia and insulin resistance. Moreover, *Adipoq*-driven Cre used in those studies also causes recombination in bone marrow stromal cells (*Mukohira et al., 2019*). Similarly, mouse models or treatments that result in BMAT expansion, such as *Prx1*-driven *Pth1r* knockout mice (*Fan et al., 2017*), CR, thiazolidinedione administration, estrogen-deficiency, and irradiation (*Li and MacDougald, 2021*), also caused bone loss, but again, effects on bone may be secondary to lack of promoter specificity or confounding systemic effects. Lineage tracing studies have previously been performed to determine cell-specific markers for BMAds. For example, both *Prx1* and *Osterix* are restricted to bone and trace to 100% of BMAds, but are also expressed in mesenchymal cells (*Logan et al., 2002*; *Mizoguchi et al., 2014*). *Nestin* and leptin receptor (*Lepr*) label over 90% of BMAds, but also trace to stromal cells (*Zhou et al., 2017*). Whereas *Pdgfr* $\alpha$  (*Pdgfra*)-driven Cre expression causes recombination in all white adipocytes, only 50–70% of BMAds are traced (*Horowitz et al., 2017*). Thus, our successful strategy for targeting BMAds using dual expression of *Osterix* and *Adipoq*, as reported in this work, improves the interpretability of experiments on the distinct roles of BMAds in the marrow niche and will be a useful tool for future investigations.

After generating this novel BMAd-specific Cre mouse model, we successfully ablated *Pnpla2* in BMAds, and demonstrated the necessity of ATGL in BMAd lipolysis. Our studies directly demonstrate for the first time the importance of BMAd lipolysis in myelopoiesis and bone homeostasis under conditions of energetic stress, including CR, irradiation, bone regeneration and cold exposure. With the loss of peripheral WAT in CR mice, there is a dramatic increase in BMAT throughout the tibia, and this is accompanied by increased expression of adipocyte genes, including those involved in lipid uptake, de novo lipogenesis, and lipolysis. BMAT expansion with CR has been observed in both rodents and humans (Cawthorn et al., 2014; Devlin et al., 2010; Fazeli et al., 2021), and mechanisms underlying this observation are still not fully understood. We speculate that CR promotes lipolysis in peripheral adipose tissues, and the released non-esterified fatty acids have increased flux to bone marrow, where they are used either directly to maintain hematopoiesis and bone homeostasis, or used indirectly after having been stored and released from BMAT. The RNAseq data also suggests that BMAds have elevated rates of lipid uptake, lipogenesis and lipolysis with CR in control mice. However, when BMAd lipolysis is impaired, this dynamic cycle is halted, which is reflected by the blunted induction of adipocyte genes in response to CR. This BMAd quiescence causes a shortfall in local energy supply and contributes to hematopoietic cell and osteoblast dysfunction. In this regard, two major collagens secreted by osteoblasts, *Col1a1* and *Col1a2*, and *Alpl* were increased by CR in control BMAd-*Pnpla2*<sup>+/+</sup> mice, but not in calorie-restricted BMAd-*Pnpla2*<sup>-/-</sup> mice. These data are consistent with the trend for thinner osteoid observed in CR BMAd-*Pnpla2*<sup>-/-</sup> mice and reduced circulating concentrations of the bone formation marker P1NP. Although bone mineralization is not impaired, new bone forming surface is reduced in CR mice that lack BMAd lipolysis. In addition, the number of osteoclasts on trabecular bone surface is higher in CR BMAd-*Pnpla2*<sup>-/-</sup> mice; however, osteoclast surface per bone surface and a circulating marker of bone turnover (CTX-1) are not increased. A serum marker for osteoclast activity, TRACP5b, is decreased in BMAd-*Pnpla2*<sup>-/-</sup> mice either fed ad libitum or a CR diet. Taken together, our studies suggest that bone mass reduction in CR BMAd-*Pnpla2*<sup>-/-</sup> mice is less likely due to degradation of bone by osteoclasts, and more likely due to impaired osteoblast function, including collagen secretion and osteoid production.

Interestingly, the contributions of BMAd lipolysis to bone homeostasis appear to be more important in male mice compared to females. Although we considered that a stronger phenotype might be revealed in female mice following estrogen depletion, the low bone mass observed with ovariectomy or CR may represent a critical threshold that is strongly defended through mechanisms independent of BMAd lipolysis. Alternatively, it is possible that androgens increase energy requirements of bone such that male mice are more dependent on BMAd lipolysis under stressful conditions. Consistent with this tenet, in both mouse and human studies of calorie restriction, males tend to have greater induction of BMAds than females (Fazeli et al., 2021). Importantly, we observed that bone volume fraction and trabecular number were increased by 12 weeks of CR in OVX mice of both genotypes, suggesting that the metabolic and anti-aging benefits of CR somehow block the bone loss associated with estrogen deficiency as mice aged to 40 weeks.

Surprisingly, despite expansion of BMAT in ad libitum-fed BMAd-*Pnpla2*<sup>-/-</sup> male and female mice, we did not observe differences in skeletal parameters, indicating that expansion of BMAT is not sufficient to cause bone loss, and that the correlation between elevated fracture risk and expansion of BMAT under a variety of clinical situations is not necessarily a causal relationship. The critical role of BMAd lipolysis in fueling osteoblasts was observed in BMAd-*Pnpla2*<sup>-/-</sup> male mice only when energy needs were high, or when the availability of dietary energy was low. Of note, cellular protein synthesis typically uses 25–30% of the oxygen consumption coupled to ATP synthesis (Rolfe and Brown, 1997), and this percentage may be higher in osteoblasts since protein synthesis and translation are integral to osteoblast function. Additionally, fatty acids contribute substantially to the energy demands of bone tissue and cells (Adamek et al., 1987), and in the absence of BMAd lipolysis, these energy needs must be met from circulating lipids, glucose, lactate, and amino acids. Uptake of fatty acids by osteoblasts is likely mediated by the CD36 fatty acid translocase, which is required in mice to maintain osteoblast numbers and activity (Kevorkova et al., 2013). Further, impairment of fatty acid oxidation in osteoblasts and osteocytes led to reduced postnatal bone acquisition in female, but not male mice. Interestingly, significant increases in the osteoid thickness, osteoid volume per bone volume, and the osteoid maturation time suggest that a mineralization defect occurs in mice unable to oxidize fatty acids obtained not only from BMAds, but also from circulation (Kim et al., 2017). Although we



have largely interpreted effects of *Pnpla2* deficiency as causing a local energy shortfall, *Pnpla2* deficiency may also alter downstream signaling activities. For example, ATGL deficiency prevents cAMP-dependent degradation of TXNIP and thus reduces glucose uptake and lactate secretion (Beg et al., 2021). ATGL-catalyzed lipolysis also provides essential mediators to increase activity of PGC-1 $\alpha$ /PPAR $\alpha$  and PPAR $\delta$  pathways (Haemmerle et al., 2011; Khan et al., 2015). Thus, it is conceivable that ATGL deficiency may alter the BMAd transcriptome and secretome to influence the marrow niche independent of its role as a fuel source.

Given the extensive literature describing interactions between BMAds and hematopoietic cells (Lee et al., 2018; Valet et al., 2020), we were surprised at the lack of substantial changes in hematopoietic progenitors, white blood cells, and red blood cells in BMAd-*Pnpla2*<sup>-/-</sup> mice under basal and CR conditions. One possibility is that skeletal sites containing low BMAd numbers, including vertebrae, sternum, ribs and pelvis, may allow compensatory formation of circulating mature blood cells (Kricun, 1985). In addition, hematopoietic progenitors and mature blood cell populations were not substantially altered in bone marrow of long bones, with the exception of myeloid differentiation into neutrophils, suggesting that hematopoietic cellularity is generally maintained despite expansion of BMAd volume. Although hematopoietic progenitors and mature cells can use lipids for energy, glucose serves as the major source of energy for glycolysis and oxidative metabolism in these cell populations (Jeon et al., 2020; Roy et al., 2018). It is perhaps unsurprising, given the importance of blood cell production in maintaining life, that there is a great deal of metabolic flexibility when it comes to fuel sources for hematopoiesis. While HSPC numbers are unaltered in our BMAd-*Pnpla2*<sup>-/-</sup> mice, myeloid lineage cell recovery is significantly blunted by CR and deficiency of BMAd-lipolysis following sublethal irradiation and in in vitro myeloid CFU assays. Myeloid progenitors from CR BMAd-*Pnpla2*<sup>-/-</sup> mice had an impaired capacity to expand, suggesting that progenitors were reprogrammed in response to energy deficiency in the bone marrow niche. We did not profile the metabolic changes of HSPCs in CR BMAd-*Pnpla2*<sup>-/-</sup> mice, but it has been reported that fatty acid oxidation is required for HSC asymmetric division to retain the stem cell properties (Ito et al., 2012).

In summary, we have developed a novel mouse model to specifically evaluate the importance of BMAds in adult life and during times of nutritional, hormonal, environmental and mechanical stress. We report that BMAds are a local energy source that support myeloid cell lineage regeneration following irradiation, and maintain progenitor differentiation capacity when systemic energy is limiting. In addition, we find that BMAd serves a highly specialized function to maintain bone mass and osteoblast function in times of elevated local energy needs such as with bone regeneration, increased whole body energy needs from cold exposure, or when dietary energy is limited due to CR. Thus, Steele's instincts in 1884 when he wrote that fat from marrow 'nourishes the skeleton' are largely borne out by modern experimentation.

## Limitations of study

There are some limitations to the BMAd-*Cre* mice that should be noted. For instance, expression of *Cre* from the IRES within the 3'-UTR of *Adipoq* is relatively low, and thus rates of recombination are less frequent in young mice than optimal. Mice that are older than 16 weeks are suggested for future usage of this *Cre* mouse model. However, bone formation and turnover rates decrease with age both in mice and humans (Fatayerji and Eastell, 1999; Ferguson et al., 2003), which may provide challenges for mechanistic studies. The IRES-*Cre* cassette also causes hypoadiponectinemia so experimental design must include appropriate controls with BMAd-*Cre* positive mice with or without floxed genes. Although a total absence of adiponectin reduces bone mass (Naot et al., 2016; Yang et al., 2019; Zhu et al., 2020), mice with hypoadiponectinemia described here did not exhibit metabolic or bone phenotypes. In retrospect, a better approach might have been to accept loss of one *Adipoq* allele and insert the FAC cassette at the start site of the adiponectin coding region to promote high levels of *Cre* expression. This strategy might also have allowed inducible knockout of BMAd genes with tamoxifen through expression of CreERT2, which we found to be too inefficient to be functional when inserted into the 3'-UTR of *Adipoq*, with only 5–8% BMAds labeled in tamoxifen-treated adult mice. Of note, all mice used in these studies were on a mixed SJL and C57BL/6 J background, and mouse strain influences bone mass, and responsiveness of bone to stressors. Although we have not provided direct evidence of BMAd-derived fatty acids fueling osteoblasts or hematopoietic cells, this line of investigation will require technical advances to distinguish BMAd-derived NEFA from those in

circulation. It should be noted that our RNAseq data was obtained from cBMAT of distal tibiae. It is likely that the fundamental interactions between BMAT and other cells within the marrow niche are similar between regions; however, we do not exclude the possibility that there may be unique interactions between rBMAT and osteoblast/hematopoietic cells.

## Materials and methods

### Resource availability

#### Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ormond A. MacDougald (<https://medicine.umich.edu/dept/molecular-integrative-physiology/ormond-macdougald-phd>).

#### Materials availability

Our *Osterix-FLPo* and *FLPo*-dependent *Adipoq-Cre* (FAC) mouse models will be available to investigators upon request. All the other data and materials that support the findings of this study are available within the article and supplemental information, or available from the authors upon request.

### Animal

#### Generation of BMAd-specific Cre mouse model

To create a BMAd-specific Cre mouse model, we expressed mouse codon-optimized FLP (FLPo) (**Raymond et al., 2007**) from the *Osterix* (*Sp7*) locus to recombine and activate a Cre expressed from the *Adipoq* locus. After designing sgRNA target sequences against 3'-UTR of endogenous *Osterix* (sgRNA: gatctgagctggtagaggaagg) and *Adipoq* (sgRNA1: tgaacaagtgagtacacgtgtgg; sgRNA2: cagt gacagaaaaatagcatgg) genes with the prediction algorithm available at <http://crispor.tefor.net>, we cloned sgRNA sequences into an expression plasmid bearing both sgRNA scaffold backbone (BB) and Cas9, pSpCas9(BB) (**Ran et al., 2013**), which is also known as pX330 (Addgene plasmid ID: 42230; Watertown, MA). Modified pX330 plasmids were injected into fertilized ova. After culture to the blastocyst stage, Cas9 activity was confirmed by sequencing the predicted cut site. We then inserted a DNA fragment containing an in-frame fusion protein between endogenous *Osterix* and *FLPo*, separated by coding sequence for P2A (porcine teschoviral-1) self-cleavage site to allow the full-length proteins to function independently. We also inserted into the 3'-UTR of *Adipoq* an *IRE5-F3-Frt-reversed Cre-F3-Frt* cassette with ~1 kb of 5' and 3' flanking homology-arm sequence. The targeting vectors (Cas9 expression plasmid: 5 ng/ul; donor DNA: 10 ng/ul) were injected into fertilized mouse eggs, which were transferred into pseudopregnant recipients to obtain pups. Tail DNA was obtained for genomic PCR and Sanger sequencing to screen F0 founders for desired genetic modifications at the expected locations. These F0 generation chimeric mice were mated with normal mice to obtain mice that are derived exclusively from the modified fertilized eggs. Germline transmitted mice (F1 generation) carrying the designated genetic modifications were bred with reporter mice to validate the activity and efficiency of FLPo and Cre recombinase. These mice were generated by University of Michigan Transgenic Animal Model Core and MDRC Molecular Genetics Core.

#### Validation of Osterix-FLPo specificity and efficiency

*Osterix-FLPo* mice were bred with FLP-dependent EGFP reporter mice (derived from <https://www.jax.org/strain/012429>; Bar Harbor, ME), provided by Dr. David Olson from the University of Michigan MDRC Molecular Genetics Core. Fresh tissue confocal was performed to validate EGFP expression.

#### Validation of the specificity and efficiency of FLPo-activated Adipoq-Cre (FAC) mice

Among 80 F0 generation pups, 13 mice carried the FAC cassette. These founder mice were bred with *Osterix-FLPo* mice and mT/mG reporter mice (Stock No. 007676, Jackson Laboratory; Bar Harbor, ME) to further validate Cre recombinase activity and specificity via fresh tissue confocal and immunofluorescent histology. Every single mouse in F1 generation was confirmed and separated for future breeding.

We finally selected F0-#693→ F1-#4376 for BMAd-specific knockout lines. Of note, *Osterix-FLPo* and *FAC* mice were generated on a mixed SJL and C57BL/6J background. *Pnp1a2<sup>fllox/flox</sup>* mice purchased from Jackson laboratory (Stock No. 024278; Bar Harbor, ME) were on a C57BL/6J background.

## Animal housing

Mice were housed in a 12 hr light/dark cycle in the Unit for Laboratory Animal Medicine at the University of Michigan, with free access to water. Mice were fed ad libitum or underwent caloric restriction, as indicated. All procedures were approved by the University of Michigan Committee on the Use and Care of Animals with the protocol number as PRO00009687.

## Animal procedures

1. 30% CR. After acclimation to single-housing for 2 weeks, and control diet (D17110202; Research Diets; New Brunswick, NJ) for a week, daily food intake was measured for another week. Mice were then fed a 30% CR diet (D19051601; Research Diets; New Brunswick, NJ) daily at ~6 pm, prior to onset of the dark cycle.
2. Ovariectomy. Female mice at 16 weeks of age underwent ovariectomy (OVX). After 2 weeks recovery, they were either fed an ad libitum or 30% CR diet for 12 weeks.
3. Proximal tibial defect. Surgeries were performed under isoflurane anesthesia, and subcutaneous 0.1 mg/kg buprenorphine was given in 12 h intervals for peri-/post-operative pain management. The proximal tibial defects were obtained by drilling a hole through anterior cortical and trabecular bone, 1–2 mm below the epiphyseal growth plate, with a 0.7 mm low-speed drill.
4. Cold exposure. Mice were single-housed without nesting materials in thermal chambers for 3 weeks at 4°C.
5. Glucose Tolerance Test (GTT). Mice were fasted overnight (16–18 hours). Body weight and fasting glucose levels were measured, followed by an intraperitoneal (i.p.) injection of glucose (1 g glucose/kg body weight). Blood glucose was measured with Bayer Contour test strips at 15, 30, 60, 90, and 120 min time points by cutting the tip of tails.
6. Whole body irradiation. Irradiations were carried out using a Kimtron IC320 (Kimtron Medical; Oxford, CT) at a dose rate of ~4 Gy/min with total dosage of 6 Gy in the University of Michigan Rogel Cancer Center Experimental Irradiation Shared Resource. Dosimetry was carried out using an ionization chamber connected to an electrometer system that is directly traceable to a National Institute of Standards and Technology calibration.

## Fresh tissue confocal microscopy

*Osterix*-driven EGFP expression and BMAd-*Cre*-driven mT/mG reporter mice were sacrificed. Fresh tissues were collected immediately and put in ice-cold PBS, which was protected from light. Soft tissues including adipose tissues and liver were cut into small pieces and placed in a chamber for confocal imaging (Nikon Ti-E Inverted Microscope; Minato City, Tokyo, Japan). Bones were bisected and butterflied on a coverslip for imaging. Both white field and fluorescent images were taken under ×200 magnification.

## Histology and histomorphometry

Tissue histology was performed essentially as described previously (Li et al., 2019). Briefly, soft tissues were fixed in formalin, and embedded in paraffin for sectioning. Tibiae were fixed in paraformaldehyde, decalcified in EDTA for at least 2 weeks, and followed by post-decalcification fixation with 4% paraformaldehyde. Bone tissues were then embedded in paraffin, sectioned. After staining with hematoxylin and eosin (H&E), soft tissues were imaged with an Olympus BX51 microscope. Bones were stained with H&E or Tartrate-Resistant Acid Phosphatase (TRAP; Sigma-Aldrich, MO) as indicated, and slides were scanned at ×200 magnification. Static measurements include bone volume fraction, trabecular bone microstructure parameters, osteoblast number and surface, and osteoclast number and eroded surface. Undecalcified tibia was used for plastic sectioning. Mineralized trabecular bone and osteoid were evaluated with Goldner's Trichrome Staining. For dynamic studies, calcein (C0857; Sigma-Aldrich, MO) dissolved in 0.02 g/ml sodium bicarbonate with 0.9% saline at 20 mg/kg was injected intraperitoneally nine- and two-days before sacrifice for quantification of mineral surface (MS), inter-label width (Ir. L. Wi), and mineral apposition rate (MAR) in tibia. Calculations were made

with Bioquant Osteo 2014 (Nashville, TN) software in a blinded manner (*Merceron et al., 2014; Morse et al., 2014*).

### **μCT analysis**

Tibiae were placed in a 19-mm diameter specimen holder and scanned over the entire length of the tibiae using a μCT system (μCT100 Scanco Medical, Bassersdorf, Switzerland). Scan settings were: voxel size 12 μm, 70 kVp, 114 μA, 0.5 mm AL filter, and integration time 500ms. Density measurements were calibrated to the manufacturer's hydroxyapatite phantom. Analysis was performed using the manufacturer's evaluation software with a threshold of 180 for trabecular bone and 280 for cortical bone.

### **Marrow fat quantification by osmium tetroxide staining and μCT**

After analyses of bone variables, mouse tibiae were decalcified for osmium tetroxide staining, using our previously published method (*Scheller et al., 2015*). In addition, a lower threshold (300 grey-scale units) was used for proximal tibial rBMAT quantification because density of osmium staining is low due to smaller adipocyte size, and with threshold as 400 grey-scale units for cBMAT in distal tibia.

### **Immunofluorescent staining**

Decalcified tibiae were embedded in OCT compound and used for frozen sectioning at 15 μm. Excess OCT was removed, and tibial tissues were blocked with 10% goat serum for one hour at room temperature. Primary antibodies for GFP (1:500) and RFP (1:200; *Figure 1F*) or ATGL (1:100; *Figure 2B*) were then added to slides and incubated with bone tissues overnight at 4°C. Secondary antibodies (goat anti-Rabbit IgG, Alexa Fluor 594 and goat anti-chicken IgG Alexa Fluor 488 or donkey anti-rabbit IgG (H+L), Alexa Fluor 488) were added to slides following three washes. Two hours later, DAPI staining was performed. Slides were mounted with prolong gold antifade reagent and imaged.

### **RNA extraction and quantitative real-time PCR (qPCR)**

RNA was extracted from tissues after powdering in liquid nitrogen and lysis in RNeasy lysis reagent in a pre-cooled dounce homogenizer. Quantitative PCR was performed using an Applied Biosystems QuantStudio 3 qPCR machine (Waltham, MA). Gene expression was calculated based on a cDNA standard curve within each plate and normalized to expression of the geometric mean of housekeeping genes *Hprt*, *Rpl32A*, and *Tbp*. qPCR primers are provided in *Supplementary file 3*.

### **Immunoblot**

Detection of proteins by immunoblot was as described previously (*Mori et al., 2021*).

### **Ex vivo lipolysis**

Distal tibial BMAT plugs were flushed out from the bone, and four plugs were pooled into one well of a 96-well plate for each n. Pre-warmed 2% BSA HBSS was added to BMAT explants with vehicle (DMSO) or forskolin (FSK, 5 μM), to activate lipolysis (*Litosch et al., 1982*). Cultured media was collected hourly for 4 hr, and glycerol and NEFA concentrations were measured with commercially available kits as listed above in reagents.

### **CFU assay**

Bone marrow cells of BMAd-*Pnpla2*<sup>+/+</sup> and BMAd-*Pnpla2*<sup>-/-</sup> mice were obtained from femur and tibia. To isolate bone marrow, the bones were flushed with IMDM (Gibco 12440; Waltham, MA) containing penicillin-streptomycin antibiotic (Gibco 15270-063; Waltham, MA). Pelleted cells were counted with a hemocytometer, 1 × 10<sup>4</sup> cells were plated in Methocult medium (Stem cell M3534; Vancouver, Canada) in 35 mm culture dishes, and cells were then incubated at 37°C in 5% CO<sub>2</sub> with ≥95% humidity for seven days. CFU-G, CFU-M and CFU-GM colonies on each plate were counted using a microscope with a 4X objective lens.

### **Bulk RNA sequencing**

Distal tibial plugs (cBMAT) from two animals were pooled together for each bulk RNAseq sample. Total RNA was isolated from BMAT for strand specific mRNA sequencing (Beijing Genomics Institute,

China). Over twenty million reads were obtained using a paired-end 100 bp module on DNBSEQ platform. The quality of the raw reads data was checked using FastQC (v.0.11.9) and the filtered reads were aligned to reference genome (UCSC mm10) using STAR with default parameters. All samples passed the post-alignment quality check (QualiMap v.2.2.1). The DESeq2 method was used for differential expression analysis with genotype (*Pnpla2*<sup>+/+</sup> vs. *Pnpla2*<sup>-/-</sup>) and treatment (CR vs. ad libitum) as the main effects. Gene ontology analysis was done using MetaScape. The Principal Component Analysis (PCA) plot was generated using the PlotPCA function building in DESeq2 package. To compare the number of differentially expressed genes between genotype/treatment groups, volcano plots were constructed using the Enhanced Volcano package under R environment. Heatmap plots were generated using pheatmap package under R environment and the complete-linkage clustering method was used for the hierarchical cluster of genes. These data are available through NCBI GEO with the following accession number, GSE183784.

## Flow cytometry

Femurs were isolated from mice. Bone marrow was harvested by flushing the femurs with 1 mL of ice-cold PEB (1 X PBS with 2 mM EDTA and 0.5% bovine serum albumin). Red blood cells were lysed once by adding 1 mL of RBC Lysis Buffer (155 mM NH<sub>4</sub>Cl, 10 mM KHCO<sub>3</sub>, 0.1 mM EDTA) and gently pipetting to mix. Cells were immediately pelleted by centrifugation and resuspended in 1 mL of ice-cold PEB. Cells were stained for 30 min in PEB buffer with the indicated antibodies below and analyzed on the BD LSRFortessa or BD FACSAria III. Data was analyzed using FlowJo software (BD Biosciences, version 10.8). Dead cells and doublets were excluded based on FSC and SSC distribution. To stain for mature leukocytes antibodies used were against CD45, Ly6G, CD11b, CD115, CD19, and CD3e. All CD45<sup>+</sup> cells were gated first for further identification. Neutrophils were defined as Ly6G<sup>+</sup>CD11b<sup>+</sup>, monocytes were defined as Ly6G<sup>-</sup>CD11b<sup>+</sup>CD115<sup>+</sup>, B cells were defined as Ly6G<sup>-</sup>CD11b<sup>-</sup>CD19<sup>+</sup>, and T cells were defined as Ly6G<sup>-</sup>CD11b<sup>-</sup>CD3e<sup>+</sup>. To stain for bone marrow neutrophil populations, antibodies used were against Ly6G, CD11b, cKit, CXCR2, CXCR4, and CD62L. Pre-neutrophils were defined as Ly6G<sup>+</sup>CD11b<sup>+</sup>cKit<sup>+</sup>, immature neutrophils were defined as Ly6G<sup>+</sup>CD11b<sup>+</sup>cKit<sup>+</sup>CXCR2<sup>lo</sup>, and mature neutrophils were defined as Ly6G<sup>+</sup>CD11b<sup>+</sup>cKit<sup>+</sup>CXCR2<sup>hi</sup>. To stain for hematopoietic stem and progenitor cells (HSPCs) antibodies used were against a lineage panel (Gr-1, CD11b, B220, CD3e, TER119), cKit, Sca-1, CD150, CD48, CD105, and CD16/32. After gating on the lineage<sup>-</sup> population, HSPCs were defined as follows; HSCs as LSKCD150<sup>+</sup>CD48<sup>-</sup>, MPPs as LSKCD150<sup>+</sup>CD48<sup>+</sup>, HPC1 as LSKCD150<sup>+</sup>CD48<sup>+</sup>, HPC2 as LSKCD150<sup>+</sup>CD48<sup>+</sup>, GMPs as LKCD150<sup>+</sup>CD16/32<sup>+</sup>, PreGMs as LKCD150<sup>+</sup>CD105<sup>-</sup>, PreMegEs as LKCD150<sup>+</sup>CD105<sup>-</sup>, and PreCFUe as LKCD150<sup>+</sup>CD105<sup>+</sup>. LSK = lineage<sup>-</sup>Sca1<sup>+</sup>cKit<sup>+</sup>, LK = lineage<sup>-</sup>cKit<sup>+</sup>.

## Bone regeneration analysis

Nine days after the proximal tibial defect surgery, proximal tibiae were collected for  $\mu$ CT scanning. After construction, new generated trabecular and cortical bone were quantified by Dragonfly software (Montréal, Canada). Under the full view of 3D and 2D images, a cylinder-shaped region of interest (ROI) was defined in trabecular or cortical bone defect area (as shown in **Figure 6A**) with 3D dimension as 0.3 mm (diameter) x 0.7 mm (height) for trabecular compartment and 0.3 mm (diameter) x 0.2 mm (height) for cortical compartment. An automatic split at otsu threshold for each bone was collect first, and then mean threshold for a whole cohort was calculated. This average threshold was applied to each bone to normalize bone volume fraction and mineral content.

## Statistics

We calculated the minimal animal number required for studies based on the mean and SD values to make sure we had adequate animals per group to address our hypothesis. All the mice were randomly assigned to the indicated groups. Although the investigators responsible for group allocation were not blinded to the allocation scheme, they were blinded to group allocation during data collection, and the investigators responsible for analyses were blinded to the allocation scheme.

Significant differences between groups were assessed using a two-sample *t*-test or ANOVA with post-tests as appropriate: one-way ANOVA with Tukey's multiple comparisons test, two-way ANOVA with Sidak's multiple comparisons test, and three-way ANOVA analysis as appropriate. All analyses were conducted using the GraphPad Prism version 9. All graphical presentations are mean +/-SD. For

statistical comparisons, a p-value of <0.05 was considered significant. All experiments were repeated at least twice.

## Acknowledgements

This work was supported by grants or fellowships from the NIH to OAM (R01 DK62876; R24 DK092759; R01 DK126230; R01 AG069795), SMR (T32 GM835326; F31 DK12272301), DPB (T32 HD007505; T32 GM007863), KS (R01DK115583), KTL (T32 DK071212; F32 DK122654), RLS (T32 DK101357; F32 DK123887), KDH (R01AR066028), and CJR (R24DK092759). ZL was supported by a fellowship from the American Diabetes Association (1–18-PDF-087) and EB from the American Heart Association (20-PAF00361). This research was also supported by a Pilot & Feasibility grant and core facilities of the Michigan Integrative Musculoskeletal Health Core Center (P30 AR069620), Michigan Diabetes Research Center (P30 DK020572), Michigan Nutrition and Obesity Center (P30 DK089503), and University of Michigan Comprehensive Cancer Center (P30 CA046592).

## Additional information

### Funding

Funder	Grant reference number	Author
National Institutes of Health	R01 DK62876	Ormond A MacDougald
National Institutes of Health	R24 DK092759	Ormond A MacDougald
National Institutes of Health	R01 DK126230	Ormond A MacDougald
National Institutes of Health	R01 AG069795	Ormond A MacDougald
National Institutes of Health	T32 GM835326	Steven M Romanelli
National Institutes of Health	F31 DK12272301	Steven M Romanelli
National Institutes of Health	T32 HD007505	Devika P Bagchi
National Institutes of Health	T32 GM007863	Devika P Bagchi
National Institutes of Health	R01DK115583	Kanakadurga Singer
National Institutes of Health	T32 DK071212	Kenneth T Lewis
National Institutes of Health	F32 DK122654	Kenneth T Lewis
National Institutes of Health	T32 DK101357	Rebecca L Schill
National Institutes of Health	F32 DK123887	Rebecca L Schill
National Institutes of Health	R01AR066028	Kurt D Hankenson
National Institutes of Health	R24DK092759	Clifford J Rosen
American Diabetes Association	1-18-PDF-087	Ziru Li

Funder	Grant reference number	Author
American Heart Association	20-PAF00361	Emily Bowers

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

### Author contributions

Ziru Li, Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Validation, Visualization, Writing - original draft; Emily Bowers, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Visualization; Junxiong Zhu, Data curation, Investigation, Methodology, Resources, Visualization; Hui Yu, Data curation, Formal analysis, Methodology, Resources, Software, Visualization; Julie Hardij, Data curation, Investigation, Visualization; Devika P Bagchi, Hiroyuki Mori, Kenneth T Lewis, Katrina Granger, Rebecca L Schill, Steven M Romanelli, Investigation; Simin Abrishami, Data curation, Methodology; Kurt D Hankenson, Kanakadurga Singer, Conceptualization, Funding acquisition, Methodology, Resources, Supervision, Writing - review and editing; Clifford J Rosen, Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing - review and editing; Ormond A MacDougald, Conceptualization, Data curation, Funding acquisition, Project administration, Resources, Supervision, Writing - review and editing

### Author ORCIDs

Ziru Li  <http://orcid.org/0000-0002-2755-9299>

Hui Yu  <http://orcid.org/0000-0001-5249-0193>

Kanakadurga Singer  <http://orcid.org/0000-0001-8278-3800>

Clifford J Rosen  <http://orcid.org/0000-0003-3436-8199>

Ormond A MacDougald  <http://orcid.org/0000-0001-6907-7960>

### Ethics

All procedures were approved by the University of Michigan Committee on the Use and Care of Animals with the protocol number as PRO00009687.

### Decision letter and Author response

Decision letter <https://doi.org/10.7554/eLife.78496.sa1>

Author response <https://doi.org/10.7554/eLife.78496.sa2>

---

## Additional files

### Supplementary files

- Supplementary file 1. BMAd-lipolysis deficiency has subtle effects on circulating mature blood cells. Whole blood from male mice at 24 weeks of age fed ad libitum (top) or a 30% CR diet for 6 weeks (bottom) was submitted for complete blood counts (CBC). White- and red- blood cell related parameters are shown. Multiple unpaired t tests had been performed crossing all parameters, *P* values were adjusted for multiple comparisons using Two-stage step-up (Benjamini, Krieger, and Yekutieli) with FDR method.
- Supplementary file 2. BMAd-lipolysis deficiency causes mild changes in bone marrow hematopoietic cells. Femoral bone marrow cells from male mice at 24 weeks of age fed ad libitum (top) or a 30% CR diet for 6 weeks (bottom) were collected and stained with antibodies for flow cytometry analyses. Mature blood cells and hematopoietic stem/progenitor cells (HSPCs) were counted. Multiple unpaired t tests had been performed crossing all parameters, *P* values were adjusted for multiple comparisons using Two-stage step-up (Benjamini, Krieger, and Yekutieli) with FDR method.
- Supplementary file 3. PCR primer list.
- MDAR checklist

### Data availability

The accession number for the BMAT bulk RNA seq data reported in this paper is GEO: GSE183784.

The following dataset was generated:

Author(s)	Year	Dataset title	Dataset URL	Database and Identifier
Li Z, Yu H, MacDougald O	2021	Bone marrow adipocyte (BMAAd)-specific deletion of Pnpla2 reveals local roles for lipolysis to fuel cells of bone and the marrow niche	<a href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE183784">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE183784</a>	NCBI Gene Expression Omnibus, GSE183784

## References

- Aaron N**, Kraakman MJ, Zhou Q, Liu Q, Costa S, Yang J, Liu L, Yu L, Wang L, He Y, Fan L, Hirakawa H, Ding L, Lo J, Wang W, Zhao B, Guo E, Sun L, Rosen CJ, Qiang L. 2021. Adipsin promotes bone marrow adiposity by priming mesenchymal stem cells. *eLife* **10**:e69209. DOI: <https://doi.org/10.7554/eLife.69209>, PMID: 34155972
- Adamek G**, Felix R, Guenther HL, Fleisch H. 1987. Fatty acid oxidation in bone tissue and bone cells in culture. *Characterization and Hormonal Influences. Biochem J* **248**:129–137. DOI: <https://doi.org/10.1042/bj2480129>
- Ahmadian M**, Abbott MJ, Tang T, Hudak CSS, Kim Y, Bruss M, Hellerstein MK, Lee H-Y, Samuel VT, Shulman GI, Wang Y, Duncan RE, Kang C, Sul HS. 2011. Desnutrin/ATGL is regulated by AMPK and is required for a brown adipose phenotype. *Cell Metabolism* **13**:739–748. DOI: <https://doi.org/10.1016/j.cmet.2011.05.002>, PMID: 21641555
- Ambrosi TH**, Scialdone A, Graja A, Gohlke S, Jank AM, Bocian C, Woelk L, Fan H, Logan DW, Schürmann A, Saraiva LR, Schulz TJ. 2017. Adipocyte Accumulation in the Bone Marrow during Obesity and Aging Impairs Stem Cell-Based Hematopoietic and Bone Regeneration. *Cell Stem Cell* **20**:771–784. DOI: <https://doi.org/10.1016/j.stem.2017.02.009>, PMID: 28330582
- Bagchi DP**, Forss I, Mandrup S, MacDougald OA. 2018. SnapShot: Niche Determines Adipocyte Character I. *Cell Metabolism* **27**:264. DOI: <https://doi.org/10.1016/j.cmet.2017.11.012>, PMID: 29320707
- Beg M**, Zhang W, McCourt AC, Enerbäck S. 2021. ATGL activity regulates GLUT1-mediated glucose uptake and lactate production via TXNIP stability in adipocytes. *The Journal of Biological Chemistry* **296**:100332. DOI: <https://doi.org/10.1016/j.jbc.2021.100332>, PMID: 33508319
- Bozec A**, Bakiri L, Jimenez M, Rosen ED, Catalá-Lehnen P, Schinke T, Schett G, Amling M, Wagner EF. 2013. Osteoblast-specific expression of Fra-2/AP-1 controls adiponectin and osteocalcin expression and affects metabolism. *Journal of Cell Science* **126**:5432–5440. DOI: <https://doi.org/10.1242/jcs.134510>, PMID: 24046454
- Cawthorn WP**, Scheller EL, Learman BS, Parlee SD, Simon BR, Mori H, Ning X, Bree AJ, Schell B, Broome DT, Soliman SS, DelProposto JL, Lumeng CN, Mitra A, Pandit SV, Gallagher KA, Miller JD, Krishnan V, Hui SK, Bredella MA, et al. 2014. Bone marrow adipose tissue is an endocrine organ that contributes to increased circulating adiponectin during caloric restriction. *Cell Metabolism* **20**:368–375. DOI: <https://doi.org/10.1016/j.cmet.2014.06.003>, PMID: 24998914
- Chen J**, Long F. 2013.  $\beta$ -catenin promotes bone formation and suppresses bone resorption in postnatal growing mice. *Journal of Bone and Mineral Research* **28**:1160–1169. DOI: <https://doi.org/10.1002/jbmr.1834>, PMID: 23188722
- Cook JR**, Semple RK. 2010. Hypoadiponectinemia--cause or consequence of human "insulin resistance"? *The Journal of Clinical Endocrinology and Metabolism* **95**:1544–1554. DOI: <https://doi.org/10.1210/jc.2009-2286>, PMID: 20164291
- Corsa CAS**, Walsh CM, Bagchi DP, Foss Freitas MC, Li Z, Hardij J, Granger K, Mori H, Schill RL, Lewis KT, Maung JN, Azaria RD, Rothberg AE, Oral EA, MacDougald OA. 2021. Adipocyte-Specific Deletion of Lamin A/C Largely Models Human Familial Partial Lipodystrophy Type 2. *Diabetes* **70**:1970–1984. DOI: <https://doi.org/10.2337/db20-1001>, PMID: 34088712
- Devlin MJ**, Cloutier AM, Thomas NA, Panus DA, Lotinun S, Pinz I, Baron R, Rosen CJ, Bouxsein ML. 2010. Caloric restriction leads to high marrow adiposity and low bone mass in growing mice. *Journal of Bone and Mineral Research* **25**:2078–2088. DOI: <https://doi.org/10.1002/jbmr.82>, PMID: 20229598
- Dobin A**, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. 2013. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics (Oxford, England)* **29**:15–21. DOI: <https://doi.org/10.1093/bioinformatics/bts635>, PMID: 23104886
- Dobin A**. 2022. STAR. c2f3c65. GitHub. <https://github.com/alexdobin/STAR>
- Duchamp de Lageneste O**, Julien A, Abou-Khalil R, Frangi G, Carvalho C, Cagnard N, Cordier C, Conway SJ, Colnot C. 2018. Periosteum contains skeletal stem cells with high bone regenerative potential controlled by Periostin. *Nature Communications* **9**:773. DOI: <https://doi.org/10.1038/s41467-018-03124-z>, PMID: 29472541
- Eguchi J**, Wang X, Yu S, Kershaw EE, Chiu PC, Dushay J, Estall JL, Klein U, Maratos-Flier E, Rosen ED. 2011. Transcriptional control of adipose lipid handling by IRF4. *Cell Metabolism* **13**:249–259. DOI: <https://doi.org/10.1016/j.cmet.2011.02.005>, PMID: 21356515
- Emont MP**, Jacobs C, Essene AL, Pant D, Tenen D, Colleluori G, Di Vincenzo A, Jørgensen AM, Dashti H, Stefek A, McGonagle E, Strobel S, Laber S, Agrawal S, Westcott GP, Kar A, Veregge ML, Gulko A, Srinivasan H, Kramer Z, et al. 2022. A single-cell atlas of human and mouse white adipose tissue. *Nature* **603**:926–933. DOI: <https://doi.org/10.1038/s41586-022-04518-2>, PMID: 35296864



- Fan Y, Hanai J-I, Le PT, Bi R, Maridas D, DeMambro V, Figueroa CA, Kir S, Zhou X, Mannstadt M, Baron R, Bronson RT, Horowitz MC, Wu JY, Bilezikian JP, Dempster DW, Rosen CJ, Lanske B. 2017. Parathyroid Hormone Directs Bone Marrow Mesenchymal Cell Fate. *Cell Metabolism* **25**:661–672. DOI: <https://doi.org/10.1016/j.cmet.2017.01.001>, PMID: 28162969
- Fatayerji D, Eastell R. 1999. Age-related changes in bone turnover in men. *Journal of Bone and Mineral Research* **14**:1203–1210. DOI: <https://doi.org/10.1359/jbmr.1999.14.7.1203>, PMID: 10404022
- Fazeli PK, Bredella MA, Pachon-Peña G, Zhao W, Zhang X, Faje AT, Resulaj M, Polineni SP, Holmes TM, Lee H, O'Donnell EK, MacDougald OA, Horowitz MC, Rosen CJ, Klibanski A. 2021. The dynamics of human bone marrow adipose tissue in response to feeding and fasting. *JCI Insight* **6**:138636. DOI: <https://doi.org/10.1172/jci.insight.138636>, PMID: 33974568
- Ferguson VL, Ayers RA, Bateman TA, Sims SJ. 2003. Bone development and age-related bone loss in male C57BL/6J mice. *Bone* **33**:387–398. DOI: [https://doi.org/10.1016/s8756-3282\(03\)00199-6](https://doi.org/10.1016/s8756-3282(03)00199-6), PMID: 13678781
- Haemmerle G, Moustafa T, Woelkart G, Büttner S, Schmidt A, van de Weijer T, Hesselink M, Jaeger D, Kienesberger PC, Zierler K, Schreiber R, Eichmann T, Kolb D, Kotzbeck P, Schweiger M, Kumari M, Eder S, Schoiswohl G, Wongsiriroj N, Pollak NM, et al. 2011. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR- $\alpha$  and PGC-1. *Nature Medicine* **17**:1076–1085. DOI: <https://doi.org/10.1038/nm.2439>, PMID: 21857651
- Horowitz MC, Berry R, Holtrup B, Sebo Z, Nelson T, Fretz JA, Lindskog D, Kaplan JL, Ables G, Rodeheffer MS, Rosen CJ. 2017. Bone marrow adipocytes. *Adipocyte* **6**:193–204. DOI: <https://doi.org/10.1080/21623945.2017.1367881>, PMID: 28872979
- Ito K, Carracedo A, Weiss D, Arai F, Ala U, Avigan DE, Schafer ZT, Evans RM, Suda T, Lee C-H, Pandolfi PP. 2012. A PML-PPAR- $\delta$  pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. *Nature Medicine* **18**:1350–1358. DOI: <https://doi.org/10.1038/nm.2882>, PMID: 22902876
- Jeon JH, Hong CW, Kim EY, Lee JM. 2020. Current Understanding on the Metabolism of Neutrophils. *Immune Network* **20**:e46. DOI: <https://doi.org/10.4110/in.2020.20.e46>, PMID: 33425431
- Kevorkova O, Martineau C, Martin-Falstra L, Sanchez-Dardon J, Brissette L, Moreau R. 2013. Low-bone-mass phenotype of deficient mice for the cluster of differentiation 36 (CD36). *PLOS ONE* **8**:e77701. DOI: <https://doi.org/10.1371/journal.pone.0077701>
- Khan SA, Sathyanarayan A, Mashek MT, Ong KT, Wollaston-Hayden EE, Mashek DG. 2015. ATGL-Catalyzed Lipolysis Regulates SIRT1 to Control PGC-1 $\alpha$ /PPAR- $\alpha$  Signaling. *Diabetes* **64**:418–426. DOI: <https://doi.org/10.2337/db14-0325>, PMID: 25614670
- Kim SP, Li Z, Zoch ML, Frey JL, Bowman CE, Kushwaha P, Ryan KA, Goh BC, Scafidi S, Pickett JE, Faugere M-C, Kershaw EE, Thorek DLJ, Clemens TL, Wolfgang MJ, Riddle RC. 2017. Fatty acid oxidation by the osteoblast is required for normal bone acquisition in a sex- and diet-dependent manner. *JCI Insight* **2**:92704. DOI: <https://doi.org/10.1172/jci.insight.92704>, PMID: 28814665
- Kricun ME. 1985. Red-yellow marrow conversion: its effect on the location of some solitary bone lesions. *Skeletal Radiology* **14**:10–19. DOI: <https://doi.org/10.1007/BF00361188>, PMID: 3895447
- Lee MKS, Al-Sharea A, Dragoljevic D, Murphy AJ. 2018. Hand of FATE: lipid metabolism in hematopoietic stem cells. *Current Opinion in Lipidology* **29**:240–245. DOI: <https://doi.org/10.1097/MOL.0000000000000500>, PMID: 29528857
- Lewis JW, Edwards JR, Naylor AJ, McGettrick HM. 2021. Adiponectin signalling in bone homeostasis, with age and in disease. *Bone Research* **9**:122. DOI: <https://doi.org/10.1038/s41413-020-00122-0>, PMID: 33414405
- Li Z., Hardij J, Bagchi DP, Scheller EL, MacDougald OA. 2018. Development, regulation, metabolism and function of bone marrow adipose tissues. *Bone* **110**:134–140. DOI: <https://doi.org/10.1016/j.bone.2018.01.008>, PMID: 29343445
- Li Z, Hardij J, Evers SS, Hutch CR, Choi SM, Shao Y, Learman BS, Lewis KT, Schill RL, Mori H, Bagchi DP, Romanelli SM, Kim K-S, Bowers E, Griffin C, Seeley RJ, Singer K, Sandoval DA, Rosen CJ, MacDougald OA. 2019. G-CSF partially mediates effects of sleeve gastrectomy on the bone marrow niche. *The Journal of Clinical Investigation* **129**:2404–2416. DOI: <https://doi.org/10.1172/JCI126173>, PMID: 31063988
- Li Z, MacDougald OA. 2021. Preclinical models for investigating how bone marrow adipocytes influence bone and hematopoietic cellularity. *Best Practice & Research. Clinical Endocrinology & Metabolism* **35**:101547. DOI: <https://doi.org/10.1016/j.beem.2021.101547>, PMID: 34016532
- Li N, Zhao S, Zhang Z, Zhu Y, Gliniak CM, Vishvanath L, An YA, Wang M-Y, Deng Y, Zhu Q, Shan B, Sherwood A, Onodera T, Oz OK, Gordillo R, Gupta RK, Liu M, Horvath TL, Dixit VD, Scherer PE. 2021. Adiponectin preserves metabolic fitness during aging. *eLife* **10**:e65108. DOI: <https://doi.org/10.7554/eLife.65108>, PMID: 33904399
- Litosch I, Hudson TH, Mills I, Li SY, Fain JN. 1982. Forskolin as an activator of cyclic AMP accumulation and lipolysis in rat adipocytes. *Molecular Pharmacology* **22**:109–115 PMID: 6289066.,
- Logan M, Martin JF, Nagy A, Lobe C, Olson EN, Tabin CJ. 2002. Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer. *Genesis (New York, N.Y)* **33**:77–80. DOI: <https://doi.org/10.1002/gene.10092>, PMID: 12112875
- Maridas DE, Rendina-Ruedy E, Helderman RC, DeMambro VE, Brooks D, Guntur AR, Lanske B, Bouxsein ML, Rosen CJ. 2019. Progenitor recruitment and adipogenic lipolysis contribute to the anabolic actions of parathyroid hormone on the skeleton. *FASEB Journal* **33**:2885–2898. DOI: <https://doi.org/10.1096/fj.201800948RR>, PMID: 30354669
- McIlroy GD, Suchacki K, Roelofs AJ, Yang W, Fu Y, Bai B, Wallace RJ, De Bari C, Cawthorn WP, Han W, Delibegović M, Rochford JJ. 2018. Adipose specific disruption of seipin causes early-onset generalised

- lipodystrophy and altered fuel utilisation without severe metabolic disease. *Molecular Metabolism* **10**:55–65. DOI: <https://doi.org/10.1016/j.molmet.2018.01.019>, PMID: 29459250
- Merceron C**, Mangiavini L, Robling A, Wilson TL, Giaccia AJ, Shapiro IM, Schipani E, Risbud MV. 2014. Loss of HIF-1 $\alpha$  in the notochord results in cell death and complete disappearance of the nucleus pulposus. *PLOS ONE* **9**:e110768. DOI: <https://doi.org/10.1371/journal.pone.0110768>, PMID: 25338007
- Mizoguchi T**, Pinho S, Ahmed J, Kunisaki Y, Hanoun M, Mendelson A, Ono N, Kronenberg HM, Frenette PS. 2014. Osterix marks distinct waves of primitive and definitive stromal progenitors during bone marrow development. *Developmental Cell* **29**:340–349. DOI: <https://doi.org/10.1016/j.devcel.2014.03.013>, PMID: 24823377
- Mori H**, Dugan CE, Nishii A, Benchamana A, Li Z, Cadenhead TS, Das AK, Evans CR, Overmyer KA, Romanelli SM, Peterson SK, Bagchi DP, Corsa CA, Hardij J, Learman BS, El Azzouny M, Coon JJ, Inoki K, MacDougald OA. 2021. The molecular and metabolic program by which white adipocytes adapt to cool physiologic temperatures. *PLOS Biology* **19**:e3000988. DOI: <https://doi.org/10.1371/journal.pbio.3000988>, PMID: 33979328
- Morse A**, McDonald MM, Kelly NH, Melville KM, Schindeler A, Kramer I, Kneissel M, van der Meulen MCH, Little DG. 2014. Mechanical load increases in bone formation via a sclerostin-independent pathway. *Journal of Bone and Mineral Research* **29**:2456–2467. DOI: <https://doi.org/10.1002/jbmr.2278>, PMID: 24821585
- Mottillo EP**, Bloch AE, Leff T, Granneman JG. 2012. Lipolytic products activate peroxisome proliferator-activated receptor (PPAR)  $\alpha$  and  $\delta$  in brown adipocytes to match fatty acid oxidation with supply. *The Journal of Biological Chemistry* **287**:25038–25048. DOI: <https://doi.org/10.1074/jbc.M112.374041>, PMID: 22685301
- Mukohira H**, Hara T, Abe S, Tani-Ichi S, Sehara-Fujisawa A, Nagasawa T, Tobe K, Ikuta K. 2019. Mesenchymal stromal cells in bone marrow express adiponectin and are efficiently targeted by an adiponectin promoter-driven Cre transgene. *International Immunology* **31**:729–742. DOI: <https://doi.org/10.1093/intimm/dxz042>, PMID: 31094421
- Muzumdar MD**, Tasic B, Miyamichi K, Li L, Luo L. 2007. A global double-fluorescent Cre reporter mouse. *Genesis (New York, N.Y.)* **45**:593–605. DOI: <https://doi.org/10.1002/dvg.20335>, PMID: 17868096
- Naot D**, Watson M, Callon KE, Tuari D, Musson DS, Choi AJ, Sreenivasan D, Fernandez J, Tu PT, Dickinson M, Gamble GD, Grey A, Cornish J. 2016. Reduced Bone Density and Cortical Bone Indices in Female Adiponectin-Knockout Mice. *Endocrinology* **157**:3550–3561. DOI: <https://doi.org/10.1210/en.2016-1059>, PMID: 27384302
- Naveiras O**, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ. 2009. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. *Nature* **460**:259–263. DOI: <https://doi.org/10.1038/nature08099>, PMID: 19516257
- Polineni S**, Resulaj M, Faje AT, Meenaghan E, Bredella MA, Bouxsein M, Lee H, MacDougald OA, Klibanski A, Fazeli PK. 2020. Red and White Blood Cell Counts Are Associated With Bone Marrow Adipose Tissue. *Bone Mineral Density, and Bone Microarchitecture in Premenopausal Women. J Bone Miner Res* **35**:1031–1039. DOI: <https://doi.org/10.1002/jbmr.3986>
- Ran FA**, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. 2013. Genome engineering using the CRISPR-Cas9 system. *Nature Protocols* **8**:2281–2308. DOI: <https://doi.org/10.1038/nprot.2013.143>, PMID: 24157548
- Raymond CS**, Soriano P, Marinus M. 2007. High-Efficiency FLP and  $\Phi$ C31 Site-Specific Recombination in Mammalian Cells. *PLOS ONE* **2**:e162. DOI: <https://doi.org/10.1371/journal.pone.0000162>, PMID: 17225864
- Riddle RC**, Clemens TL. 2017. Bone Cell Bioenergetics and Skeletal Energy Homeostasis. *Physiological Reviews* **97**:667–698. DOI: <https://doi.org/10.1152/physrev.00022.2016>, PMID: 28202599
- Robles H**, Park S, Joens MS, Fitzpatrick JAJ, Craft CS, Scheller EL. 2019. Characterization of the bone marrow adipocyte niche with three-dimensional electron microscopy. *Bone* **118**:89–98. DOI: <https://doi.org/10.1016/j.bone.2018.01.020>, PMID: 29366839
- Rolfe DF**, Brown GC. 1997. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. *Physiological Reviews* **77**:731–758. DOI: <https://doi.org/10.1152/physrev.1997.77.3.731>, PMID: 9234964
- Roy IM**, Biswas A, Verfaillie C, Khurana S. 2018. Energy Producing Metabolic Pathways in Functional Regulation of the Hematopoietic Stem Cells. *IUBMB Life* **70**:612–624. DOI: <https://doi.org/10.1002/iub.1870>, PMID: 29999238
- Sárvári AK**, Van Hauwaert EL, Markussen LK, Gammelmark E, Marcher A-B, Ebbesen MF, Nielsen R, Brewer JR, Madsen JGS, Mandrup S. 2021. Plasticity of Epididymal Adipose Tissue in Response to Diet-Induced Obesity at Single-Nucleus Resolution. *Cell Metabolism* **33**:437–453. DOI: <https://doi.org/10.1016/j.cmet.2020.12.004>, PMID: 33378646
- Scheller EL**, Doucette CR, Learman BS, Cawthorn WP, Khandaker S, Schell B, Wu B, Ding S-Y, Bredella MA, Fazeli PK, Khoury B, Jepsen KJ, Pilch PF, Klibanski A, Rosen CJ, MacDougald OA. 2015. Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues. *Nature Communications* **6**:7808. DOI: <https://doi.org/10.1038/ncomms8808>, PMID: 26245716
- Scheller EL**, Khandaker S, Learman BS, Cawthorn WP, Anderson LM, Pham HA, Robles H, Wang Z, Li Z, Parlee SD, Simon BR, Mori H, Bree AJ, Craft CS, MacDougald OA. 2019. Bone marrow adipocytes resist lipolysis and remodeling in response to  $\beta$ -adrenergic stimulation. *Bone* **118**:32–41. DOI: <https://doi.org/10.1016/j.bone.2018.01.016>, PMID: 29360620
- Schoiswohl G**, Stefanovic-Racic M, Menke MN, Wills RC, Surlow BA, Basantani MK, Sitnick MT, Cai L, Yazbeck CF, Stolz DB, Puliniilkunnil T, O'Doherty RM, Kershaw EE. 2015. Impact of Reduced ATGL-Mediated Adipocyte Lipolysis on Obesity-Associated Insulin Resistance and Inflammation in Male Mice. *Endocrinology* **156**:3610–3624. DOI: <https://doi.org/10.1210/en.2015-1322>, PMID: 26196542

- Shen W**, Chen J, Punyanitya M, Shapses S, Heshka S, Heymsfield SB. 2007. MRI-measured bone marrow adipose tissue is inversely related to DXA-measured bone mineral in Caucasian women. *Osteoporosis International* **18**:641–647. DOI: <https://doi.org/10.1007/s00198-006-0285-9>, PMID: 17139464
- Steele JD**. 1884. Hygienic Physiology. A. S. Barnes and Co.
- Valet C**, Batut A, Vauclard A, Dortignac A, Bellio M, Payrastra B, Valet P, Severin S. 2020. Adipocyte Fatty Acid Transfer Supports Megakaryocyte Maturation. *Cell Reports* **32**:107875. DOI: <https://doi.org/10.1016/j.celrep.2020.107875>, PMID: 32640240
- Vogler JB**, Murphy WA. 1988. Bone marrow imaging. *Radiology* **168**:679–693. DOI: <https://doi.org/10.1148/radiology.168.3.3043546>, PMID: 3043546
- Wang F**, Mullican SE, DiSpirito JR, Peed LC, Lazar MA. 2013. Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPAR $\gamma$ . *PNAS* **110**:18656–18661. DOI: <https://doi.org/10.1073/pnas.1314863110>, PMID: 24167256
- Yang J**, Park OJ, Kim J, Han S, Yang Y, Yun CH, Han SH. 2019. Adiponectin Deficiency Triggers Bone Loss by Up-Regulation of Osteoclastogenesis and Down-Regulation of Osteoblastogenesis. *Frontiers in Endocrinology* **10**:815. DOI: <https://doi.org/10.3389/fendo.2019.00815>, PMID: 31824428
- Zhou BO**, Yu H, Yue R, Zhao Z, Rios JJ, Naveiras O, Morrison SJ. 2017. Bone marrow adipocytes promote the regeneration of stem cells and haematopoiesis by secreting SCF. *Nature Cell Biology* **19**:891–903. DOI: <https://doi.org/10.1038/ncb3570>, PMID: 28714970
- Zhu J**, Liu C, Jia J, Zhang C, Yuan W, Leng H, Xu Y, Song C. 2020. Short-term caloric restriction induced bone loss in both axial and appendicular bones by increasing adiponectin. *Annals of the New York Academy of Sciences* **1474**:47–60. DOI: <https://doi.org/10.1111/nyas.14380>, PMID: 32469430
- Zou W**, Rohatgi N, Brestoff JR, Zhang Y, Scheller EL, Craft CS, Brodt MD, Migotsky N, Silva MJ, Harris CA, Teitelbaum SL. 2019. Congenital lipodystrophy induces severe osteosclerosis. *PLOS Genetics* **15**:e1008244. DOI: <https://doi.org/10.1371/journal.pgen.1008244>, PMID: 31233501
- Zou W**, Rohatgi N, Brestoff JR, Li Y, Barve RA, Tycksen E, Kim Y, Silva MJ, Teitelbaum SL. 2020. Ablation of Fat Cells in Adult Mice Induces Massive Bone Gain. *Cell Metabolism* **32**:801–813. DOI: <https://doi.org/10.1016/j.cmet.2020.09.011>, PMID: 33027637

## Appendix 1

## Appendix 1—key resources table

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Strain, strain background ( <i>Mus musculus</i> , SJLxC57BL/6J)	Osterix-FLPo	Generated in University of Michigan Transgenic Animal Model Core	Donated to JAX: Stock No. 037208	Male and female
Strain, strain background ( <i>Mus musculus</i> , SJLxC57BL/6J)	FLPo-dependent <i>Adipoq</i> -Cre (FAC)	Generated in University of Michigan Transgenic Animal Model Core	N/A	Male and female
Strain, strain background ( <i>Mus musculus</i> , SJLxC57BL/6J)	Frt-flxed EGFP	Generated in University of Michigan Transgenic Animal Model Core	N/A	Male and female
Strain, strain background ( <i>Mus musculus</i> , C57BL/6J)	mT/mG	Jackson Laboratory	Stock No. 007676	Male and female
Strain, strain background ( <i>Mus musculus</i> , C57BL/6J)	<i>Pnpla2</i> <sup>fllox/fllox</sup>	Jackson Laboratory	Stock No. 024278	Male and female
Antibody	Anti-Adiponectin (rabbit monoclonal)	Sigma-Aldrich	A6354	WB (1:1000)
Antibody	Anti-FABP4/A-FABP Antibody (goat polyclonal)	R&D Systems	AF1443	WB (1:1000)
Antibody	Anti-alpha Tubulin Antibody (rat monoclonal)	Thermo Fisher Scientific	MA180017	WB (1:1000)
Antibody	Anti-ERK 2 Antibody (mouse monoclonal)	Santa Cruz Biotechnology	sc-1647	WB (1:1000)
Antibody	Anti-Albumin antibody (rabbit monoclonal)	Abcam	Ab207327	WB (1:1000)
Antibody	Anti-ATGL Antibody (rabbit polyclonal)	Cell Signaling Technology	2138S	WB (1:1000)
Antibody	Anti-ATGL Antibody (rabbit monoclonal)	Abcam	ab207799	IF (1:100)
Antibody	Anti-GFP antibody (chicken polyclonal)	Abcam	ab13970	IF (1:500)
Antibody	Anti-RFP Antibody Pre-adsorbed (rabbit polyclonal)	Rockland	600-401-379	IF (1:200)
Antibody	Goat anti Rabbit IgG (H+L) Secondary Antibody, Alexa Fluor 594 (goat polyclonal)	Invitrogen	A11012	IF (1:100)
Antibody	Alexa Fluor 488 goat anti-chicken IgG (H+L) (goat polyclonal)	Invitrogen	A11039	IF (1:100)

Appendix 1 Continued on next page

## Appendix 1 Continued

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Antibody	Anti-Ly6G FITC (rat monoclonal)	BD Biosciences	551460	FACS (1:200)
Antibody	Anti-CD11b APC (rat monoclonal)	Invitrogen	17-0112-82	FACS (1:200)
Antibody	Anti-CD115 APC-Cy7 (rat monoclonal)	Biolegend	135531	FACS (1:100)
Antibody	Anti-CD3e PE-Cy7 (Armenian Hamster monoclonal)	Biolegend	100319	FACS (1:200)
Antibody	Anti-CD19 Pacific Blue (rat monoclonal)	Invitrogen	48-0193-82	FACS (1:200)
Antibody	Anti-CD45 AlexaFluor700 (rat monoclonal)	BD Biosciences	560510	FACS (1:200)
Antibody	Anti-Gr-1 Biotin (rat monoclonal)	Biolegend	79750	FACS (1:200)
Antibody	Anti-CD11b Biotin (rat monoclonal)	Biolegend	79749	FACS (1:200)
Antibody	Anti-B220 Biotin (rat monoclonal)	Biolegend	79752	FACS (1:200)
Antibody	Anti-CD3e Biotin (Armenian Hamster monoclonal)	Biolegend	79751	FACS (1:200)
Antibody	Anti-TER119 Biotin (Armenian Hamster monoclonal)	Biolegend	79748	FACS (1:200)
Antibody	Anti-Sca1 PE-Cy7 (rat monoclonal)	Invitrogen	25-5981-82	FACS (1:200)
Antibody	Anti-cKit (CD117) APC-Cy7 (rat monoclonal)	Biolegend	105826	FACS (1:100)
Antibody	Anti-CD150 BrilliantViolet 421 (rat monoclonal)	Biolegend	115925	FACS (1:200)
Antibody	Anti-CD48 FITC (Armenian Hamster monoclonal)	Invitrogen	11-0481-85	FACS (1:100)
Antibody	Anti-CD16/32 PerCP-Cy5.5 (rat monoclonal)	Biolegend	101324	FACS (1:200)
Antibody	Anti-CD105 APC (rat monoclonal)	Biolegend	120413	FACS (1:200)
Antibody	Anti-CXCR2 PE (rat monoclonal)	Biolegend	149304	FACS (1:200)
Antibody	Anti-CXCR4 PE-Dazzle (rat monoclonal)	Biolegend	146514	FACS (1:100)
Antibody	Anti-CD62L BrilliantViolet 421 (rat monoclonal)	Biolegend	104435	FACS (1:200)

Appendix 1 Continued on next page

Appendix 1 Continued

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Commercial assay or kit	Acid Phosphatase Leukocyte (TRAP) Kit	Sigma-Aldrich	387A-1KT	
Commercial assay or kit	Free Glycerol Determination Kit	Sigma-Aldrich	FG0100	
Commercial assay or kit	NEFA Reagent (NEFA-HR(2))	FUJIFILM Wako Diagnostics	NC9517309	
Commercial assay or kit	BCA Protein Assay Kit	Thermo Fisher Scientific	23225	
Commercial assay or kit	RAT/MOUSE P1NP ELISA KIT	Immunodiagnostic Systems Inc	NC9666468	
Commercial assay or kit	Mouse TRANCE/RANK L/TNFSF11 Quantikine ELISA Kit	R&D Systems	MTR00	
Commercial assay or kit	MOUSE TRAP ASSAY	Immunodiagnostic Systems Inc	NC9360739	
Commercial assay or kit	MethoCult GF M3534	ATEMCELL	03534	
Commercial assay or kit	DNA-free Kit	Life Technologies	AM1906	
Chemical compound, drug	Calcein	Sigma-Aldrich	C0875	
Chemical compound, drug	EDTA	DOT Scientific Inc	dse57020	
Chemical compound, drug	Tetroxide Osmium	Electron Microscopy Sciences	19190	
Chemical compound, drug	Forskolin	Cayman Chemical Company	11018	
Chemical compound, drug	Bovine Serum Albumin (BSA), Fraction V	Gold Biotechnology	A-421–250	
Chemical compound, drug	qPCRBio SyGreen Mix Hi-ROX Blue	Innovative Solutions	4SPB20.16	
Chemical compound, drug	PCRBio HS Taq Mix Red	Innovative Solutions	4SPB10.23	
Chemical compound, drug	Agarose	Thermo Fisher Scientific	BP160-500	
Chemical compound, drug	RNA STAT-60	AMSBIO	CS-502	
Chemical compound, drug	M-MLV Reverse Transcriptase	Thermo Fisher Scientific	28025013	
Chemical compound, drug	100bp DNA Ladder	NEB	N3231S	
Software, algorithm	Microsoft Office	Microsoft		<a href="https://its.umich.edu/communication/collaboration/microsoft-office-365/getting-started">https://its.umich.edu/communication/collaboration/microsoft-office-365/getting-started</a>

Appendix 1 Continued on next page

Appendix 1 Continued

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Software, algorithm	Adobe photoshop	Adobe	<a href="https://www.adobe.com/creativecloud/desktop-app.html">https://www.adobe.com/creativecloud/desktop-app.html</a>	
Software, algorithm	Prism 9	GraphPad software	<a href="https://www.graphpad.com/">https://www.graphpad.com/</a>	
Software, algorithm	Image J	Image J	<a href="https://imagej.nih.gov/ij/">https://imagej.nih.gov/ij/</a>	
Software, algorithm	MetaMorph	BioVision Technologies	<a href="https://www.biovis.com/metamorph.html">https://www.biovis.com/metamorph.html</a>	
Software, algorithm	Scano $\mu$ CT 100	SCANCO Medical AG	<a href="https://www.scanco.ch/">https://www.scanco.ch/</a>	
Software, algorithm	BIOQUANT OSTEO	BIOQUANT Image analysis corporation	<a href="https://bioquant.com/">https://bioquant.com/</a>	
Software, algorithm	STAR	PMID:23104886	<a href="https://github.com/alexdobin/STAR">https://github.com/alexdobin/STAR</a> ; <b>Dobin et al., 2013</b> ; <b>Dobin, 2022</b>	
Software, algorithm	DESeq2	PMID:25516281	<a href="https://bioconductor.org/packages/release/bioc/html/DESeq2.html">https://bioconductor.org/packages/release/bioc/html/DESeq2.html</a>	
Software, algorithm	QualiMap-2	PMID:26428292	<a href="https://qualimap.conesalab.org">https://qualimap.conesalab.org</a>	
Software, algorithm	R	The R Foundation	<a href="https://www.r-project.org/">https://www.r-project.org/</a>	
Software, algorithm	Metascape	PMID:30944313	<a href="https://metascape.org/gp/index.html">https://metascape.org/gp/index.html</a>	
Software, algorithm	Dragonfly	ORS - OBJECT RESEARCH SYSTEMS	<a href="https://www.theobjects.com/dragonfly/index.html">https://www.theobjects.com/dragonfly/index.html</a>	
Software, algorithm	FlowJo	BD Biosciences	<a href="https://www.flowjo.com/solutions/flowjo">https://www.flowjo.com/solutions/flowjo</a>	
Other	Streptavidin BrilliantViolet 510	Biolegend	405233	FACS (1:200)
Other	Element HT5 Veterinary Hematology Analyzer	Heska	<a href="https://www.heska.com/product/element-ht5/">https://www.heska.com/product/element-ht5/</a>	Service provided by UMICH In-Vivo Animal Core (IVAC)
Other	FACS Aria III cell sorter	BD Biosciences	N/A	Shared equipment in UMICH Flow Cytometry Core
Other	LSRFortessa Cell Analyzer	BD Biosciences	N/A	Shared equipment in UMICH Flow Cytometry Core
Other	Nikon A1 Confocal Microscope	Nikon	N/A	Shared equipment in UMICH Microscopy and Imaging Analysis Core (MIAC) Michigan Diabetes Research Center

Appendix 1 Continued on next page

## Appendix 1 Continued

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Other	Bayer Contour Next Test Glucose Strips	Diabetic Corner	ByrContournext	<a href="https://www.contournextone.com/siteassets/pdf/web85688006_cntrxtone_ug_r01-17.pdf">https://www.contournextone.com/siteassets/pdf/web85688006_cntrxtone_ug_r01-17.pdf</a>
Other	Scanco $\mu$ CT 100 micro-computed tomography system	SCANCO Medical AG	<a href="https://www.scanco.ch/">https://www.scanco.ch/</a>	Service provided by UMICH School of Dentistry MicroCT Core
Other	Olympus BX51	Olympus	N/A	<a href="https://www.olympus-lifescience.com/en/microscope-resource/primer/techniques/fluorescence/bx51fluorescence/">https://www.olympus-lifescience.com/en/microscope-resource/primer/techniques/fluorescence/bx51fluorescence/</a>
Other	StepOnePlus Real-Time PCR System	Thermo Fisher Scientific	4376600	<a href="https://www.thermofisher.com/order/catalog/product/4376600">https://www.thermofisher.com/order/catalog/product/4376600</a>
Other	Microtome	Leica	RM2235	<a href="https://www.leicabiosystems.com/en-br/histology-equipment/microtomes/leica-rm2235/">https://www.leicabiosystems.com/en-br/histology-equipment/microtomes/leica-rm2235/</a>
Other	Slide scanner	Nikon	N/A	Shared equipment in UMICH Orthopaedic Research Laboratories (ORL) Histology Core